Molecular Dissection of the Cellular Reponse to Dengue Virus Infection by Warke, Rajas V.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2008-04-14 
Molecular Dissection of the Cellular Reponse to Dengue Virus 
Infection 
Rajas V. Warke 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Cells Commons, Chemical Actions and Uses Commons, Genetic Phenomena Commons, 
Hemic and Immune Systems Commons, Pathology Commons, and the Viruses Commons 
Repository Citation 
Warke RV. (2008). Molecular Dissection of the Cellular Reponse to Dengue Virus Infection. GSBS 
Dissertations and Theses. https://doi.org/10.13028/ejzp-pa94. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/366 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 
Molecular Dissection of the Cellular Response to Dengue Virus Infection 
 
 
 
 
 
 
 
 
 
 
 
 
A Dissertation Presented 
 
By 
 
 
Rajas V. Warke 
 
 
 
 
 
 
 
 
Submitted to the Faculty of the 
 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
 
in partial fulfillment of the requirements for the degree of  
 
 
DOCTOR OF PHILOSOPHY 
 
In 
 
IMMUNOLOGY AND VIROLOGY 
 
APRIL 14, 2008 
 
 
 
  i
Molecular Dissection of the Cellular Response to Dengue Virus Infection
A Dissertation Presented
Rajas V. Warke
Approved as to style and content by:
Paul Clapham, Ph. , Chair of Committee
Neal Silverman, Ph. , Member of Committee
Christopher Sassetti, Ph. , Member of Commttee
Ana-Femandez-Sesma, Ph. , Member of Committee
Irene Bosch, Ph. , Thesis Advisor
Anthony Carrthers, Ph.
Dean of the Graduate School of Biomedical Sciences
Program in Immunology and Virology
Aprill4 , 2008
COPYRIGHT NOTICE 
 
Parts of this dissertation have appeared in separate publications: 
 
Warke RV, Xhaja K, Martin KJ, Fournier MF, Shaw SK, Brizuela N, de Bosch N, 
Lapointe D, Ennis FA, Rothman AL, Bosch I. Dengue virus induces novel changes in 
gene expression on human umbilical vein endothelial cells. J Virol. 2003 
Nov;77(21):11822032. 
 
Ramirez-Ortiz ZG, Warke RV, Pacheco L, Xhaja K, Sarkar D, Fisher PB, Shaw SK, 
Martin KJ, Bosch I. Discovering innate immunity genes using differential display: a story 
of RNA helicases. J Cell Physiol. 2006 Dec;209(3):636-44. 
 
Warke RV, Martin KJ, Giaya K, Shaw SK, Rothman AL, Bosch I. TRAIL is a novel 
antiviral protein against dengue virus. J Virol. 2008 Jan;82(1):555-64.  
 
Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I. Elevated levels of soluble 
ST2 protein in dengue virus infected patients. Cytokine. 2008 Feb;41(2):114-20 
 
Warke RV, Becerra A, Zawadzka A, Schmidt D, Martin KJ, Giaya K, Dinsmore JH, 
Woda M, Hendricks G, Levine T, Rothman AL, Bosch I. Efficient Dengue Virus 
(DENV) Infection of Human Muscle Satellite Cells Up-Regulates Type I IFN Response 
Genes And Differentially Modulates MHC I Expression on Bystander AND DENV-
infected Cells. J Gen Virol. In Press 
 
Becerra A, Warke RV, Martin KJ, Xhaja K, de Bosch N, Rothman AL, Bosch I. Role of 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the inhibition of 
proinflammation induced by DENV. Submitted to Infection and Immunity for review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  iii
 
ACKNOWLEDGEMENTS 
 
 
After I finished my thesis defense talk, many professional colleagues told me that 
I should be given the award for the best and the longest acknowledgements in the history 
of UMASS Medical School. I was happy to hear that since I consider myself lucky 
enough to have family and friends who have helped me along every step of the way. 
 
As I contemplate on the number of people who have made this possible for me, I 
realize how important these people have been in my success.  
 
First and foremost, I will like to thank Dr. Francis Ennis for reminding me always 
to look at the “BIG PICTURE” while designing experiments and interpreting the 
implications of experimental data.  
 
I would like to thank Dr. Irene Bosch, my thesis advisor, for giving me the 
freedom to think outside the box. I was always allowed to question any scientific 
hypothesis as long as the alternative was logical. I am quite amazed at her fighting spirit 
and her capacity to absorb and learn from failure and continue her scientific endeavor to 
understand neglected diseases and hopefully help find treatment to diseases. Hopefully, I 
have learned these virtues from her.  
 
Dr. Alan Rothman has also been instrumental is my success during my graduate 
research. He always made sure that my feet were grounded and I was not over-
interpreting the experimental data. Alan has instilled qualities like asking questions, hard 
work and ethics in me. 
 
I am grateful to my TRAC committee members for guiding me to stay focused 
and answer questions using scientifically sound experiments. They always told me that I 
was underselling my data and the amount of work I had done. These encouraging 
remarks always kept me motivated. 
 
I would also like to acknowledge all the past and present members of CIDVR who 
have been my family for the last six years supporting me personally and scientifically 
through my journey at UMASS Medical School. I cannot thank them enough. 
 
I will also like to thank Kris Giaya who practically runs the lab since my advisor 
traveling quite often. I would like to thank Kris for guiding through my personal issues. 
Also, I am grateful to Kathy J. Martin without whom the project success would not have 
been possible.   
 
I am quite lucky to have had great friends around me during all stages of my 
education supporting me and helping me stay steady during times of failure. I will miss 
Diego a lot for all the FUN, agreements, disagreements, discussions and sometimes 
  iv
arguments we have had over very diverse tips over the last eight years. Also, I will miss 
Alex, Hema and Serena for their support and criticism for the time they have known me.  
  
I am grateful to Dan and Erin for accepting me as I am. I will miss them a lot 
when I go back to India. I thank them for unconditionally supported me through my 
troubled times. 
 
To Sheetal Chaudhari, I salute for agreeing to take the journey of life with me as 
her partner and believing in me more than I believe in myself. She is my strongest 
supporter and my steadfast partner. 
 
Finally but not the least, I would like to thank my parents and family for 
unconditionally loving me and for never giving up on me. My sister always told me what 
Thomas Edison had quoted “Genius is 99 percent perspiration and one percent 
inspiration”. I would like to thank my uncle Dr. Ghanashyam Patil for reminding me the 
famous words “The harder I work, the luckier I get” by Henry Ford. I would be nothing 
without my parents support. 
 
Today when I look back at my graduate school, I realize that in any journey, the 
journey itself is more important and than the result.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  v
ABSTRACT 
 
The immune response to viral infection involves a complexity of both innate and 
adaptive pathways at the cellular and the molecular level. There are many approaches to 
begin to define the pathways at work to control viral pathogenesis. The approach favored 
in this thesis was to conduct a broad screen of the innate immune response at the gene 
expression level of infected cells.  
The innate immune response is critical to the control of viral infections.  Type I 
interferons (IFN), IFNα and IFNβ, are antiviral proteins that are an integral part of the 
innate immune response. Furthermore, by virtue of their effects on maturation and 
activation of antigen-presenting cells, IFNs are a pivotal link between the innate and 
adaptive immune systems. Most cell types produce type-I IFN when exposed to viruses. 
However, viruses have evolved multiple strategies to suppress IFN production or 
signaling. It is imperative to understand the virus-host interaction at the molecular level 
in order to identify as yet unknown mechanisms of the host antiviral response; these 
additional pathways may be useful in counteracting the viral suppression of IFN.  Type-I 
IFNs regulate expression of at least five hundred genes, suggesting a complex network of 
signaling pathways. Depending on the cell type different proteins regulate the induction 
of IFN or the expression of IFN-inducible genes. Identification of proteins that induce 
selected IFN-inducible genes may provide synergistic activity with or may have an 
advantage over type-I IFN for anti-viral therapy in the future. 
Many diseases are untreatable if identified late in their progression. In resource-
limited countries, many diseases are diagnosed clinically, which can lead to incorrect or 
delayed diagnosis and treatment. The identification of biomarkers of disease has the 
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potential to guide the correct therapy in a timely fashion. The objective of this thesis was 
to identify novel anti-viral therapies and disease biomarkers for dengue virus (DENV) 
infection. 
DENV is a mosquito-borne positive-sense single-stranded RNA virus, which 
causes an estimated 50 million infections annually. Most DENV infections result in a 
febrile illness called Dengue fever (DF). Less frequently, infections cause Dengue 
hemorrhagic fever (DHF), a potentially fatal vascular leakage syndrome associated with 
the production of pro-inflammatory cytokines. At present patients infected with DENV 
can only be treated by intravenous fluid support to prevent hypovolemia and hypotensive 
shock. This treatment is less effective in severe cases if the diagnosis is delayed. 
Identification of therapeutics with both antiviral and immune-modulatory activity may 
lower patient mortality and reduce the burden of DENV on society.  
DENV infection is cleared in most individuals after a short period of viremia 
{Libraty, 2002 #2225}. Based on in vitro and mouse models, type-I and type-II IFN 
signaling pathways are thought to be critical in the regulation of DENV infection. Higher 
serum levels of type I and type II IFNs during acute DENV infection in patients lend 
support to the above hypothesis {Kurane, 1993 #2152; Libraty, 2002 #2225}. 
To understand the DENV-human host cell interaction at the molecular level, we 
performed global gene expression analysis on DENV-infected primary human cells using 
Affymetrix GeneChips (HG-U133A). We studied dendritic cells (DC), monocytes, B 
cells and human umbilical vein endothelial cells (HUVECs), all of which are known to be 
permissive to DENV infection. We first identified genes commonly regulated in multiple 
cell types in response to DENV infection; we hypothesized that understanding this 
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common gene expression profile would identify signaling pathways involved in 
regulation of viral spread, activation of immune cells or induction of inflammation. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), one of the 23 common 
response genes, was identified as a key link between type I and type II interferon 
response genes. Pretreatment of cells with recombinant TRAIL (rTRAIL) inhibited 
DENV replication in monocytes, B cells, HUVECs and DCs. Using the DC infection 
model, we showed that this inhibition of viral replication was apoptosis-independent. 
Type-I IFN receptor (IFNR) blocking experiments showed that signaling through the 
type-I IFN receptor played an important role in the antiviral activity of exogenous 
rTRAIL. Furthermore, TRAIL also significantly reduced the expression of mRNA and 
protein of pro-inflammatory cytokines (TNFα, MIP-1β and IFNα) and chemokines 
(MCP-2, IP-10 and IL-6) in response to DENV infection. The data that TRAIL inhibits 
both viral replication and pro-inflammatory cytokine production suggest that TRAIL has 
therapeutic value in dengue. 
The endothelial cell is the site of pathology in DENV infection in vivo (vascular 
permeability and plasma leakage). To understand the direct effect of DENV infection on 
endothelial cells and its role in the induction of genes regulating vascular permeability, 
we compared gene expression in DENV-infected HUVECs to that of uninfected cells and 
cells infected with other RNA and DNA viruses, including flaviviruses (West Nile, 
yellow fever, and Japanese encephalitis viruses), bunyaviruses (Sin Nombre and Hantaan 
viruses), Epstein-Barr virus and vaccinia virus. Among the genes confirmed for their 
differential expression, ST2 (Interkeukin-1 receptor-like-1 protein-IL1RL1) and 
indoleamine 2,3-dioxygenase (IDO) were identified to be upregulated specifically in 
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response to DENV infection. Higher serum soluble ST2 (sST2) levels were detected in 
DENV-infected patients than in patients with other febrile illnesses (OFI) at the end of 
the febrile stage and at defervescence (p=0.0088 and p=0.0004, respectively). In addition, 
patients with secondary DENV infections had higher serum sST2 levels compared with 
patients with primary DENV infections (p=0.047 at the last day of fever and p=0.030 at 
defervescence). Higher levels of IDO activity (p<0.02) were also detected in dengue 
patient serum during the febrile stage of the disease as compared to OFI patient serum. 
Treatment of cells with 1-methyl-tryptophan, an antagonist of IDO, reversed the 
inhibitory effect of IFNγ on DENV replication, suggesting that IDO activity is important 
for IFN-γ mediated antiviral function against DENV. These data suggest that sST2 and 
IDO may have value as biomarkers for acute DENV infection. 
In conclusion, global gene expression analysis identified novel proteins with 
promising characteristics for the treatment and/or diagnosis of DENV infection. Although 
further studies will be needed to validate the clinical utility of TRAIL, sST2, and IDO, 
these studies demonstrate the utility of this unbiased genomics approach to identify 
therapies to currently incurable diseases. 
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 Chapter I 
 
Introduction 
 
Dengue - A Disease of Global Importance 
 
Dengue virus (DENV) is an arthropod-borne flavivirus, which has re-emerged 
as a major global health problem, particularly among children. DENV infection is 
either an epidemic or endemic health threat in many tropical and sub-tropical areas 
like South-East Asia, South America and Africa. Each year about 50-100 million 
people are infected with DENV, 500,000 cases of DHF are hospitalized and 20,000 to 
50,000 people die of DENV infection, mostly children (68, 71). Moreover, the lack of 
proper diagnostics and inability to control mosquito populations makes it a major 
public health issue in the developing world where this disease is prevalent. No 
preventative therapy such as vaccines or anti-viral treatments is currently available 
for DENV infections currently, despite its major impact on the world population. 
Timely treatment, through intravenous hydration along with close medical 
monitoring, reduces the mortality due to dengue infections. DENV infection is 
clinically defined either as dengue fever (DF), a milder form of the disease or dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS), more severe and 
potentially fatal forms of the disease. All four antigenically distinct serotypes of 
DENV [DENV1, DENV2, DENV3 and DENV4] are able to infect and produce all 
grades of the disease. Infection with one serotype of DENV induces life-long 
immunity only to the infecting serotype. Secondary infections with any other serotype 
(heterologous serotype) of DENV inducing ADE and a heterologous T-cell response 
has been hypothesized to cause DHF/DSS, the severe forms of the disease. A large 
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number of people in the tropical countries have already been exposed to DENV 
infection. This presents complications in the design of an effective vaccine. Currently, 
the concept of a tetravalent vaccine is being implemented with yet, no implications of 
protection in humans as of yet.  
The mechanisms that underlay the DENV infection induced immune 
pathology have not yet been deciphered completely. Moreover, the type of cells and 
tissues infected are being investigated currently. Severe vascular permeability and 
elevated pro-inflammatory cytokines have been demonstrated during severe dengue 
infections (97, 229). Since DENV infection-mediated pathology (plasma leakage) is 
observed when the virus already has disappeared from the systemic circulation, 
theoretically a strong antiviral agent against DENV administered early in the disease 
would prevent the occurrence of pathology associated with severe cases of DENV 
infection. Limiting the levels of circulating virus should also help reduce the 
transmission of DENV by mosquitoes biting dengue-infected individuals. Hence, 
identification of novel antiviral agents to treat the disease is a priority for research 
studies on DENV. In addition, identification of markers of severity, early during 
infection would help begin the right line of therapy to reduce disease severity. 
Role of Innate Immune Response in DENV Infection  
Animal models are extensively used to find vaccines and new treatments to 
various diseases. Due to the lack of a true animal model for DHF it has been 
challenging to propose effective therapies although vaccine research has taken place 
in non-human primates.  However, the non-human primate model of dengue infection 
does not provoke the immune activation mediated pathology seen in humans. As a 
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consequence, research studies on DENV are largely focused on clinical samples 
(cells, serum or plasma) to find correlates of disease, or in vitro infection models. 
Various research groups are developing a DENV mouse model but DENV-infected 
mice weakly support virus replication and do not present with clinical symptoms 
observed in human DENV-infected patients (116). Findings from in vitro and mouse 
studies have suggested that the innate immune response plays an important role in the 
control of spread of DENV. Moreover, innate immune response cytokines are 
expressed at higher levels in DENV-infected patient serum and or plasma during the 
acute stage of the disease. For example, higher IFNα and IFNγ protein levels are 
detected in DENV patient serum (111, 112). In vitro and mouse models of DENV 
infection have shown that IFNα and IFNγ are important for control of DENV 
replication (51, 52, 193, 194).  
The main objective of the present work was to define the molecular 
determinants of the cellular response to dengue virus. We hypothesized that gene 
expression analysis of DENV-infected primary human cells known to be permissive 
to DENV infection would provide information about host response genes involved in 
inhibition of viral replication, activation of the immune cells or in disease 
pathogenesis, by identifying genes that are differentially regulated in response to 
DENV infection. We selected primary human monocytes, B cells, dendritic cells and 
endothelial cells (HUVECs), which are known to be targets for DENV infection in 
vivo (92, 104, 107, 117, 230). DENV infection has been previously shown to activate 
these cells inducing expression and/or release of adhesion molecules, pro-
inflammatory chemokines and cytokines (30, 154). However at the individual cell 
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level, DENV infection induces inefficient maturation and activation of infected 
monocyte-derived DCs (DCs) and muscle satellite cells, respectively as compared to 
neighboring uninfected bystander DCs or muscle satellite cells (125, 166)(Warke RV 
et al. J Gen, Virol,In Press). 
In vitro studies in primary human cells and studies in mice have shown that 
the innate immune response is critical to limit levels of and spread of DENV. Based 
on these findings, our group postulates that a common innate immune response in the 
cells susceptible to DENV infection will limit DENV replication and spread. To 
identify common signaling pathways activated or repressed in monocytes, B cells and 
HUVECs we isolated RNA from DENV-infected and uninfected cells and then 
hybridized the labeled RNA to GeneChips and analyzed the gene expression data 
using gene analysis software.  We identified a set of 23 genes commonly upregulated 
in all cell types studied in response to DENV infection. Most of the genes in the 
common gene expression profile are regulated upstream either by type-I or type-II 
IFN signaling pathways. Tumor necrosis factor receptor apoptosis inducing ligand  
(TRAIL), or Tumor necrosis factor, superfamily member 10 (TNFSF10), was one of 
the 23 common response genes identified as a potential common linker for most of 
the common profile genes. TRAIL expression was detected only in DENV antigen-
negative DCs (bystander cells) suggesting that TRAIL expression was inhibited in 
DENV-infected DCs. We further found that TRAIL functions as an antiviral protein 
during DENV infection in an apoptosis-independent manner (224). In addition, the 
experiments on mechanism of action of TRAIL antiviral activity suggest that TRAIL 
inhibits DENV by an IFNα dependent (majority) and independent mechanism. 
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Furthermore, exogenous recombinant TRAIL inhibited the production of pro-
inflammatory chemokines (MCP-2, IP-10 and IL-6) and cytokines (TNFα, MIP-1β), 
suggesting an anti-inflammatory function for TRAIL as well. 
 The endothelium is the target site for DENV infection-mediated pathology 
such as vascular permeability, capillary fragility (evidenced by positive tourniquet 
test done in patients), bleeding, coagulopathy and hypovolemic shock during the 
acute phase of DHF/DSS. In vivo, the pathophysiology clinically observed is 
considered to be a result of both direct (viral infection) and indirect (pro-
inflammatory cytokines, chemokines released by activated leukocytes) effects on 
endothelial cells. We were interested in understanding the endothelial cell responses 
to DENV infection. 
With the goal of identifying unique molecular markers of DENV infection in 
endothelial cells, we performed global gene expression analysis in HUVECs infected 
with DENV or with other RNA or DNA viruses. We identified a set of 30 genes 
upregulated mostly in DENV-infected HUVECs. However, some of the genes were 
also differentially regulated in HUVECs infected with related flaviviruses, Yellow 
Fever virus (YFV) and hantavirus, a bunyavirus. Among these 33 potential DENV 
infection response genes, we selected two genes, sST2 and IDO (indoleamine 2,3-
dioxygenase), for further study. The dengue patient PBMCs used to confirm the 
relative specificity of these genes were obtained with NIH approved clinical protocols 
and consents in the dengue clinics of Venezuela and Thailand, from established 
collaborations with Dr. Alan Rothman and Dr. Norma de Bosch. We confirmed the 
specificity of sST2 and IDO upregulation following DENV infection at the mRNA by 
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quantitative reverse transcriptase PCR (qRT-PCR). Serum sST2 levels (ELISA) and 
IDO activity (mass spectrometry) were both able to distinguish patients with dengue 
from patients with other febrile illnesses (OFI) or healthy individuals. In addition, the 
data suggest that sST2 can differentiate between primary and secondary DENV 
infections. Blocking IDO enzyme activity by addition of 1-methyl tryptophan, a 
competitive inhibitor of IDO inhibited a significant level of the IFNγ-mediated 
antiviral activity against DENV. These results indicate that IDO might play an 
important role in the antiviral function of IFNγ against DENV.  
In summary, we identified novel antiviral molecules, TRAIL and IDO, with 
possible in vivo application as therapeutic agents against dengue. The ability of 
TRAIL to suppress the production of pro-inflammatory cytokines, which have been 
implicated in dengue disease pathogenesis, provides further support for its potential 
therapeutic value. We also identified two potential novel serum markers (sST2 and 
IDO) for DENV infection. Serum sST2 is the first biomarker described that might 
allow discrimination of secondary DENV infections from primary DENV infections. 
These data may improve the prospects of identification and treatment of future DENV 
infections. 
Identification of Novel Cellular Targets for DENV Infection 
Symptomatically, patients with dengue often present with general muscle 
affection as well as severe, persisting myalgia, head-ache and rash (35, 70). Higher 
serum levels of creatine and elevated creatine-phosphokinase (CPK), which is 
specifically produced by muscle cells may be elevated in DENV patients (98, 134, 
177). Similar to DENV infection, individuals affected with Chikungunya virus 
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present with persisting myalgia (35, 70, 226). A recent study involving muscle 
biopsies of acutely infected individuals demonstrated that Chikungunya virus infects 
muscle satellite cells in patients during acute phase of the disease (165). These 
findings suggest that myalgia, muscle weakness and elevated serum CPK levels in 
dengue might be a result of direct viral infection of muscle satellite cells. Hence, we 
performed flow cytometry, immunoflourescence and plaque assay to determine 
susceptibility of muscle satellite cells (CD56 and desmin positive) (6) to DENV. 
Results from these experiments demonstrate that primary human muscle satellite cells 
are susceptible to in vitro DENV infection and also support replication of DENV. 
 This Introduction gives an overview of the dengue virus, viral genome, life 
cycle and cells susceptible to DENV infection. A section that explains the aspects of 
innate and adaptive immune response activated during DENV infection follows. A 
very brief explanation of the disease, its clinical stages (DF, DHF/DSS) of DENV 
infection and the host factors involved in protection or pathogenesis during DENV 
infection are discussed in the next section. An overview of various global gene 
expression tools and how these tools have been applied to understand dengue virus 
infection follows. The last section of the Introduction is dedicated to providing 
previously published information on genes (TRAIL, ST2 and IDO) to put our 
findings in a global perspective of these protein functions.  
 
Dengue Virus (DENV) Genome and Life cycle 
Dengue is the most rapidly expanding arboviral disease in the tropics and 
subtropics. Almost half of the world’s population is estimated to be at risk, with an 
  7
estimated 50 million infections a year. One million severe dengue cases were reported 
for the Americas in 2005. There are currently close to 70 countries reporting dengue 
cases to the World Health Organization from Asia, Africa and the Americas (157). 
Proteins such as GRP78, DC-SIGN, glycosaminoglycans like heparan 
sulphate, heat shock proteins, CD14-associated molecules and mannose receptor 
(MR) have been proposed as human cellular receptors for DENV (38, 93, 141, 178, 
211). Several studies have shown that the C-type lectin dendritic cell specific 
adhesion molecule-3 (ICAM-3) grabbing non-integrin (DC-SIGN, CD209) mediates 
the high rate of dengue virus infection in DCs, which naturally express DC-SIGN 
(158, 211).  
DENV is an enveloped, single-stranded positive-sense RNA virus. The ~11 kb 
genome, which is capped at the 5’ end, encodes 10 (seven non-structural and 3 
structural) proteins. The viral genome is initially translated as a single polyprotein, 
which is then cleaved into structural (C, PrM/M and E) and non-structural (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins by viral and host proteases. 
DENV is thought to enter the cell via receptor-mediated endocytosis. Following 
endocytosis, acidification of the endosome initiates the conformational change of E to 
form trimers that exposes the active site for fusion with the membrane. The inner side 
of the vesicle membrane and the viral membrane fuse, allowing the formation of a 
pore which as it opens releases the RNA attached to the viral nucleocapsid into the 
cytoplasm. Once in the cytosol the viral RNA disassociates from the viral 
nucleocapsid, which allows for initiation of viral translation. The structural protein E 
and non-structural (NS) NS1 protein contain signal sequences for insertion into the 
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ER membrane where host and viral proteases cleave them (20, 202). The PrM and E 
proteins translocate into the ER lumen while the capsid protein remains associated 
with the ER on the cytoplasmic side. The remainder of the NS proteins localize in the 
cytoplasm, also possibly nuclear, in the case of NS5 (173) due to its DNA binding 
domains. Virion assembly occurs at the ER membrane; the E and M proteins undergo 
modifications in the Golgi and the infectious viral progeny are exocytosed via 
secretory vesicles. 
Also, stable transfection of DENV non-permissive cells with DC-SIGN or 
MR makes them susceptible to DENV infection (141). Among the seven NS proteins, 
which are part of viral genome, NS3 (viral protease, RNA replication and capping of 
viral RNA) and NS5 (RNA-dependent RNA polymerase, viral RNA capping) are the 
two largest proteins. The NS1 protein has complement fixing activity and serum 
levels of NS1 protein correlate with the severity of the disease (9). NS2A protein 
functions to cleave NS1 and NS2B proteins (83).  Also, NS2A, NS4A and NS4B 
proteins have been shown to interfere with type-I IFN signaling pathway so that the 
virus can evade the innate immune system (152, 153). 
 
Cellular Targets for DENV Infection  
In vivo cellular targets for DENV infection have not been extensively studied. 
DENV is often not detected systemically when the hemorrhagic symptoms, vascular 
permeability and plasma leakage occur. Since bleeding and vascular fragility are a 
part of infection-mediated pathology, collection of biopsy samples of internal organs 
is not considered safe for the patient. Some autopsy studies have been performed to 
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identify the cell types susceptible to DENV infection in vivo. The limitation of 
autopsy studies is that not all cell types that support DENV survival during the acute 
stage of the infection may stain positive for DENV. Monocytes have for a long period 
of time been considered the primary sites for DENV infection (107). Recently, 
circulating B cells were shown to be targets for DENV infection in DENV patients 
(104) and hepatocytes, sinusoidal endothelial cells and lung vascular endothelium 
also have stained positive for DENV antigen (92) in autopsy studies. Wu et al. made a 
major contribution to the field by demonstrating that DENV infects skin-resident 
Langerhans cells and monocytes-derived dendritic cells (230). Immature DCs 
(Langerhans cells) that reside in the dermis (the site of the mosquito bite), interstitial 
dendritic cells and precursor interstitial dendritic cells (CD14+ interstitial cells) have 
been shown to efficiently uptake DENV (117, 230). 
The high susceptibility of dendritic cells to DENV infection has been 
attributed to the expression of DC-SIGN. Mannose receptor (MR) was recently 
identified as another putative receptor for DENV in monocytes (141). Furthermore, in 
U937 and K562 cell lines, FcγRI and FcγRII receptors can increase virus uptake by 
the phenomenon of ADE (130). Hence, it is not clear whether there is a single 
specific receptor for entry of DENV into susceptible cells. 
Due to the lack of a good animal model for DENV infection, primary cells 
and cell lines have been exposed to DENV in vitro to identify susceptible cell types. 
Mast cells, fibroblasts and activated T cells have been shown to be susceptible to 
DENV infection in vitro (113, 139). Moreover, we have found that primary muscle 
satellite cells are highly susceptible to DENV infection in vitro (Warke et al. J Gen 
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Virol. In press).  Cell lines derived from different lineages, including 293 (epithelial), 
293T (type), HepG2 (hepatoma), U937 (monocytic), K562 (kidney embryonic), 
HPMEC1.1 (endothelial), and ECV304 (epithelial) can be infected with DENV in 
vitro. DENV infection of 293T cells, ECV304 cells and monocytes induced 
expression of IL-8 transcriptionally through the trans-activation of its promoter by 
NFκB (24).  
DENV mediates endothelial cell activation via both direct infection and 
indirectly as a result of cytokine induction (10, 50, 92, 201). The endothelium forms 
the primary barrier of the circulatory system and functional dysregulation of 
endothelial cells during acute dengue disease is thought to contribute to dengue 
pathology. Monocytes are important targets for DENV infection and are thought to 
play a critical role in the ADE model of dengue pathogenesis. In vivo, DENV RNA 
and antigen have been detected in multiple cell types. (85, 92, 104, 230).  
Among the accepted sites for DENV infection and replication in vivo, DCs are 
most highly susceptible to DENV infection in vitro, which can be determined by 
various techniques (125, 166, 230). In addition, DCs are important in initiation and 
modulation of the innate and adaptive immune response. Hence, DC is a good in vitro 
cell model to study the effects of DENV infection on DENV-infected and bystander 
cells.  
 
Muscle Satellite Cells as Targets for DENV Infection 
No clinical report published to date has looked at presence of DENV in 
muscle cells. However, a clinical study found that seven (44%) out of sixteen patients 
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positive for acute DENV infection clinically and serologically (IgM ELISA), 
presented with acute flaccid weakness (98). These seven DENV-positive patients had 
an incidence of acute motor quadriplegia along with elevated serum levels of CPK 
and SGPT, muscle weakness, pain and tenderness, which are findings consistent with 
myositis (98). In addition, Rajajee et al. found that 50% of the children presenting 
with clinical and laboratory features of benign acute childhood myositis were positive 
for DENV by serological tests (PAN BIO, DUO IgM and IgG capture ELISA) (177). 
Furthermore, Malheiros SM et al. detected moderate perivascular mononuclear 
infiltrate in twelve out of fifteen muscle biopsies performed in serologically positive 
DENV-infected individuals (134). These studies indicate that human skeletal muscle 
cells are indirectly or directly damaged during the acute stage of DENV infection. 
Previous studies of DENV infection in mice have also reported biochemical and 
ultrastructural changes in skeletal muscle (156, 177) as well as detected infectious 
DENV progeny in the muscles (5). Also, fatal myocarditis has been observed during 
acute DENV infection (Dr. Iris Villalobos, Dr. Jairo Rodriguez, personal 
communication).  
  
Immune Response to DENV Infection 
(i) Innate Immune Response 
The innate immune response plays an important role in the recognition of 
pathogens, for example, in initiating a potent antiviral response to virus infection. 
Uptake of the pathogen by antigen-presenting cells (dendritic cells, macrophages) 
activates the pro-inflammatory response as well as the type-I IFN signaling pathway 
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that is the upstream regulator of antiviral response genes. Type-I IFNs (α/β), which 
are produced by most cell types, play a central role in the innate antiviral response to 
a wide variety of viruses including DENV. However, since type-I IFNs can modulate 
maturation and activation of dendritic cells (46, 189), they perform a vital function to 
bridge the innate and adaptive parts of the host immune response. Type-II IFN (IFNγ) 
also can induce expression of antiviral genes. However, most of the type-II IFN is 
produced by activated NK and T cells and not by virus infected cells.  
NK cells are an important piece of the innate immune response partly by 
producing massive amounts of IFNγ. NK cells upregulate their expression of 
activation markers (CD69, HLA-DR and CD38), adhesion molecules (CD44, CD11a) 
and cytotoxic granules (TIA-1) early during the acute phase of dengue disease (11). 
However, the role of NK cells in the regulation of DENV infection has not been 
studied in depth. Higher levels of type-I and type-II IFNs have been detected in 
dengue patient serum during the acute stage of the disease (111, 112). Intravenous 
DENV (D2S10) infection in AG129 mice, which lack both type-I IFN and type-II 
IFN receptors, resulted in productive infection and TNFα-mediated lethal disease 
(195). Also, in the in vitro model of dendritic cell infection with DENV, IFNα and 
IFNγ inhibited viral replication even though it has been shown that DENV infection 
inhibits type-I IFN signaling within infected cells (78, 152, 153).  
 
(ii) Adaptive Immune Response 
The adaptive immune response involves antibodies and T lymphocytes. 
Depending on the serotype of DENV both aspects of adaptive immunity have been 
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associated with secondary DENV infection-mediated pathogenesis (159, 179). 
Passive transfer of antibodies to E, NS1 and prM proteins has been shown to protect 
mice against lethal DENV challenge (60, 118). Cross-reactive antibodies from 
previous DENV infections at sub-neutralizing concentrations can increase uptake of 
non-neutralized virus by binding to FcRII on cell surface (120).A study by Kliks et al. 
found high DEN-2 antibody-dependent enhancing activity as a risk factor for DHF 
(106). However, studies by Endy et al. (58) and laoprasopwattana K et al. (120) did 
not find a correlation between titers of preexisting neutralizing DENV-antibodies and 
the severity of the secondary infections. 
During secondary DENV infections, cross-reactive T cells presumably 
generated from the previous DENV infection proliferate more than the T cells 
specific to the newly infecting serotype (145). This phenomenon is called “Original 
antigenic sin”. DENV serotype cross-reactive cytotoxic T cells show higher avidity 
for antigen and, as compared to DENV serotype-specific cytotoxic T cells, produce 
higher pro-inflammatory cytokines like IFNγ and TNFα (55). Furthermore, other 
cytokines like IL-2, IL-10 and IL-8, which can be produced by T cells, are elevated 
before the onset of plasma leakage (112). The altered immune response and higher 
production of pro-inflammatory cytokines during a heterologous secondary infection 
might play a role in vascular leakage and activation of the coagulation cascade. 
 
Protection 
The longevity of the protection afforded by primary DENV infection against 
the homologous serotype is not completely understood. The major target for antibody 
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response is to the E protein of DENV virion. In vitro antibodies against E protein both 
inhibit viral binding to cells and neutralize infectious virus (181). Furthermore, 
passive transfer of antibodies to E protein can protect mice against challenge with 
DENV (100). IFNα and IFNγ were found to be critical for early and late immune 
response and resistance to DENV infection in mice, respectively (194). Further, a 
mouse-adapted strain of DENV injected peritoneally killed IFNα/β- and IFNγ-
deficient mice (94). IFNα can inhibit DENV replication in multiple cell types in vitro 
(51, 52, 78). However, IFNα cannot block DENV replication if added after DENV 
infection suggesting that DENV has evolved to counter IFNα’s antiviral effects. IFNγ 
also strongly inhibits DENV replication in DCs, but unlike IFNα, IFNγ treatment 
after DENV infection can still inhibit virus replication (78). Overall, immune 
responses and their effects to limit DENV replication are hypothesized to be 
protective against the development of the severe form of the disease.  
 
Clinical Stages of DENV Infection 
DENV infection, which has an incubation time of 3-7 days, is asymptomatic 
in a majority of individuals.  Dengue fever (DF), Dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS) are three major classifications for grades of 
severity of dengue disease. DHF is further sub-classified into grades I, II, III and IV 
by the World Health Organization (WHO). Grades III and IV constitute DSS. 
However, positive tourniquet test, one of the minimal criterion to diagnose a case as 
DHF has been unsuccessful in discriminating between DF and DHF effectively in 
multiple studies. In two studies, only 18% and 61% of the children with shock met 
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the criteria classified by WHO for DHF (14, 170). Hence, prominent researchers in 
the field are in favor of modifying the current WHO standards of dengue 
classification (48). 
 
Dengue Fever 
DF is a mild, self-limited febrile illness typically associated with the following 
symptoms: retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, 
leukopenia and headache. Most of the individuals recover after the acute febrile 
period, which may last from 2 to 10 days, without any specific treatment (68). There 
is lower risk of death in DENV patients presenting clinical symptoms for DF. 
 
Dengue Hemorrhagic Fever 
DHF is a more severe manifestation of DENV infection and can be caused by 
all four serotypes of DENV. A minority of people (~3%) infected with DENV 
develop this more severe form of disease according to the WHO classification criteria 
(68). During the febrile phase of the disease, patients present with similar clinical 
symptoms as DF. However, at the time of defervescence or shortly afterward, patients 
with DHF abruptly develop a vascular permeability/plasma leakage syndrome 
associated with thrombocytopenia, a bleeding diathesis. Vascular leakage and 
increased endothelial cell permeability resolve following the acute phase of the 
disease, suggesting dysfunction rather than structural damage to endothelial cells 
during DHF. A majority of cases of DHF are associated with secondary DENV 
infections (114) (DHF.CAB Int.Oxford,1997). Studies have found that children of 
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ages 4 years and above are at higher risk of developing DHF following DENV 
infection while children under 3 years of age who were seropositive for DENV did 
not present clinical symptom of infection (73). However, the cause of this DENV 
infection-mediated pathogenesis is not well understood. “Original Antigenic Sin” and 
“Antibody Dependent Enhancement” models have been postulated to be the 
immunopathogenesis mechanisms that lead to increased severity of disease (145, 
149). The cytokine profile resulting from heterologous immunity might add to the 
inflammation-induced immunopathogenesis (55, 145). Recent clinical studies have 
provided data suggesting that certain DENV genotypes are associated with DHF (55). 
The two models of pathogenesis are further explained in detail in the 
“Immunopathogenesis” section of the introduction.    
 
Dengue Immunopathogenesis 
Activation of the immune response associated with the ADE and original 
antigenic sin models during heterologous DENV infection might be responsible for 
the immunopathogenesis observed during DHF/DSS. Antibodies produced during 
primary DENV infection bind to virions of heterologous DENV serotypes during 
subsequent (secondary) infections. In vitro studies have shown that macrophages but 
not DCs (125, 230) efficiently uptake these virus-antibody complexes, which leads to 
an increase in viral replication by a phenomenon called antibody-dependent 
enhancement (ADE). Moreover, antibodies from a previous infection can also cause 
immune activation via innate immune reactions and complement activation (233). 
Levels of T cell expansion are also enhanced during secondary DENV infections (55, 
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145). However, expansion of lower-avidity memory T cells over high-avidity naïve T 
cells specific for the infecting serotype generates a more inflammatory and less 
cytotoxic T cell cytokine and chemokine response called original antigenic sin (145). 
Sub-optimal viral clearance and disturbance of homeostasis of the blood clotting 
system might occur. In addition, ADE might lead to increased DENV antigen 
presentation to T cells that might further contribute to the activation of inefficient T 
cells and the immunopathology of heterologous secondary DENV infections. 
Circulating levels of pro-inflammatory cytokines and chemokines like TNFα, IL6, 
IL-2, IL8 and MCP1 and regulators of inflammation like IL-10 and sST2 are further 
correlated with a severe outcome during acute stage of the disease (17, 37, 63, 65, 96, 
121, 176). 
 This overview on DENV and factors associated with the disease presented in 
the introduction shows that large bodies of experiments have been performed to 
understand the dengue disease. These studies have found that viral and many host 
factors correlate either with protection or pathogenesis during DENV infection. 
However, due to the absence of a reliable animal model, the significance of these 
correlations associated with the pathogenesis is not well understood. Hence, current 
focus in the field of dengue research is to understand the molecular changes effected 
by DENV infection to identify aspects of host immune response that can be induced 
or inhibited to develop a prophylactic or therapeutic vaccine against dengue.  
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Gene Expression Analysis as a Tool for Discovering Genes Involved in the 
Cellular Response to Infection 
Global gene expression analysis using reverse transcription differential 
display (RT-DD), subtractive hybridization or DNA microarays followed by 
quantitative RT-PCR is an approach that has been successfully used to identify 
candidate differentially expressed genes to understand host response to pathogens or 
disease (191, 199, 225). This approach allows for the identification of markers of 
disease and / or severity of a disease. RT-DD has advantages over subtractive 
hybridization because it requires small amounts of sample, is relatively fast, simpler 
and allows simultaneous detection of genes from the control and sample group (23). 
However, many RT-DD experiments are required to cover the entire transcriptome. In 
contrast, microarray analysis provides expression patterns of thousands of genes at 
once (20,000-40,000). Hence, the major advantage of microarray over RT-DD and 
subtractive hybridization is that it can identify multiple genes and reveal multiple 
functional signaling pathways in a single experiment. Significant conclusions can be 
obtained from a minimum of 2 microarrays using the right statistical analysis.  
 Our lab used DD and Affymetrix oligonuceotide microarray analyses followed 
by qRT-PCR (225) to study gene expression changes in HUVECs during infection 
with DENV. Using these 2 techniques, we identified several genes, some of which 
were involved in the innate antiviral response. Researchers have also identified 
upregulation of cellular support for pathogen replication and downregulation of MHC 
expression using microarrays, which can allow the pathogen to escape the immune 
system (47, 190). A microarray study on Salmonella enterica typhimurium showed 
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induction of genes involved in cell cycle arrest and cell death (49). Genomic analyses 
have also been used to understand innate and adaptive immunity, to diagnose 
pathogens, tumors, metabolic pathways and to understand the efficacy of a drug and 
vaccine research (29). Recently, Fink et al. and Popper et al. have reported gene 
expression profiles of in vitro infected cells and PBMCs of acute infected dengue 
patients, respectively (61, 198). Very encouraging findings from these two other 
groups were found as some of the genes reported in their study coincided with our 
analysis. Simmons et al. also observed lower abundance of type I interferon inducible 
genes in gene transcripts associated with DSS as compared to non-DSS patients. In 
addition to human cell analysis, Sariol et al. have looked at PMBCs from rhesus 
monkeys infected with dengue virus and found that interferon response genes are 
highly expressed in infected rhesus monkey PBMCs (182).  
 
New Antiviral, Immunomodulatory and Biomarker Proteins Identified in this 
Thesis 
 This thesis identified TRAIL as a promising candidate for further study using 
genomic analysis in primary human cells susceptible to DENV infection (224). 
Genomic and proteomic analysis approach also discovered sST2 and IDO as potential 
biomarkers for DENV infection (17).  
Here we present published information on TRAIL, ST2 and IDO genes, which 
are identified as antiviral, immunomodulatory or biomarker proteins against DENV.   
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(i) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
TRAIL (APO2L, TNFSF10) is a member of the TNF family that specifically 
promotes apoptosis in cancerous (tumor) cells by binding to and activating the death 
receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) (44, 84). Two decoy receptors 
DcR1/DR6 and DcR2/DR7 and intracellular proteins c-FLIP, XIAP, G1P3 and p38αγ 
are regulators of the signaling downstream of the two TRAIL death receptors (3, 39, 
129, 221). TRAIL is a 32.5 kDa protein composed of 281 amino acids, and is a type 
II membrane glycoprotein, with a signal peptide at the N-terminus (147). The first 38 
amino acids are intracellular and transmembrane, while the C terminus of the protein 
(39-281) is extracellular. The extracellular domain of TRAIL binds the TRAIL 
receptors DR5 and DR4 producing a trimeric structure that activates signaling 
downstream of the two death receptors (34). TRAIL protein is not only secreted into 
the extracellular space but also can localize on the surface of the cell or be stored in 
the cytoplasmic compartment of the cell (56, 147, 219, 224). Monleon I et al. 
observed that APO2L/TRAIL is stored inside cytoplasmic compartments 
approximately 500 nm in diameter, with characteristics of multivesicular bodies 
(microvesicles) (147). However, the origin of the soluble form is not fully 
understood. In their study anti-CD59 Ab stimulation induced release of TRAIL 
containing microvesicles into the supernatant. However, TRAIL was localized in 
plasma-membrane-enriched/secretory-granule fraction in neutrophils (103). Overall, 
the origin of soluble TRAIL in other systems is not understood. The expression of 
both TRAIL and TRAIL-Rs is differentially regulated in PBMCs (56, 74). Activation 
of either of the two death receptors results in recruitment of adaptor protein FADD 
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(Fas-associated death domain). TRAIL receptors are widely expressed (74, 167); thus 
most tissues and cell types are potential targets for TRAIL. FADD recruits 
procaspase-8 into the death receptor complex, thereby causing autoproteolytic 
cleavage of procaspase-8, which in turn activates the apoptosis signaling pathway 
(213).  
In vitro and in vivo studies have demonstrated tumoricidal activity of TRAIL 
without significant toxicity toward normal cells or tissues (171, 184). TRAIL-
mediated killing of EMCV and HCMV infected but not uninfected cells has been 
demonstrated (183, 188). In addition, blocking TRAIL protein delayed the clearance 
of influenza virus in mice (89). TRAIL-mediated killing of tumor cells by NDV, 
reovirus and HCV has also been shown (40) (57) (43).  
TRAIL has also been shown to negatively regulate innate immune responses 
and inflammation independent of apoptosis (54, 82, 185, 200, 218). TRAIL induction 
of ERK/Akt activation is mainly associated with proliferation and survival of 
endothelial cells (186) and can induce proliferation of T cells and synovial fibroblasts 
(148, 197). 
IFNs enhance the expression of TRAIL, while, on the other hand, TRAIL 
treatment can enhance expression of IFN-inducible genes like IFITM1, IFIT1, 
STAT1, LGal3BP, and PRKR as well as IFN-β itself (108). Hence, TRAIL binding to 
its receptors activates downstream signaling pathways that can affect any one of the 
above-mentioned cellular responses, depending on the activation and inhibition of the 
regulators of the TRAIL signaling pathway.  
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(ii) Indoleamine 2,3-dioxygenase (IDO) 
IDO is an enzyme ubiquitously distributed in mammalian tissues and cells. It 
catalyzes the initial and rate-limiting step in the catabolism of L-tryptophan along the 
kynurenine pathway (210). IFNγ (12) and LPS (62) can induce expression of IDO 
while IL-4 represses its expression (155). Other cytokines such as IFNα/β, TNF-α 
and IL-1 cannot induce IDO expression individually. However, TNF-α and IL-1 
enhance IDO expression induced by IFNγ (150). Overall, IFNγ is the most potent 
known inducer of IDO expression (180). IDO activity is also induced under 
pathological conditions such as viral and bacterial infections (45, 237), allograft 
rejection (140) and tumor development (217). IDO-expressing cells inhibit T cell 
proliferation and function by depleting L-tryptophan in the surrounding 
microenvironment (150). This process is termed “immunosuppression by starvation”. 
T cells stop proliferating in a tryptophan-reduced microenvironment since this 
tryptophan-sensitive checkpoint is at the G1 phase of the cell cycle (150). Studies in 
the Th1-mediated trinitrobenzene sulphonic acid-induced colitis model (69) 
demonstrated that 1-MT treatment to block IDO activity abolished tolerance. In 
addition, tumor and allogenic fetal rejection models (151, 217) have directly shown 
that 1-MT treatment abolishes tolerance in vivo. Uyttenhove et al. (217) found that 
tumors partly resist attack by tumor-specific CTLs through the expression of IDO, 
which leads to the degradation of tryptophan in the tumor microenvironment. The 
same study also demonstrated that, in addition to tumor cells, tumor-infiltrating 
dendritic cells but not tumor-specific CTLs stained for IDO.  
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IFNγ-induced activation of IDO has been shown to restrict Toxoplasma gondii 
growth in human microvascular endothelial cells (45). In addition, a recent study by 
Adams et al. (4) showed that IFNγ-induced IDO expression restricts herpes simplex 
virus (HSV) replication in human astrocytes (4).  
 
(iii) Interleukin-1 receptor like-1 (IL1RL1 or ST2) 
The Interleukin-1 receptor like-1 (IL-1RL-1, ST2) protein is a member of the 
interleukin-1 receptor (IL-1R) family of proteins. It was originally detected as one of 
the primary response genes in growth-stimulated murine fibroblasts (BALB/c-3T3) 
(214, 236) and as a HA-ras oncogene-responsive gene (228). Alternative splicing of 
the gene generates three mRNAs, corresponding to a longer membrane-anchored 
form (ST2L), a shorter released form (sST2) and a membrane bound variant form 
(ST2V) (21, 215, 235). The expression of the three forms has been detected in various 
human tissues and cells, including hematopoietic and endothelial cells (109). ST2L 
has been proposed as a marker for Th2 CD4+ T cells since it is selectively expressed 
on Th2 but not on Th1 CD4+ T cells (231, 234) and might be involved in the effector 
phase of Th2 immune responses (216). The sST2 protein can be induced in vitro by 
pro-inflammatory stimuli like lipo-polysaccaride (LPS), IL-1β, TNFα and IL-6 in 
human and murine inflammatory models(109, 208). In mice, the production of pro-
inflammatory cytokines precedes sST2 expression (164). Elevated levels of sST2 are 
found in patients with inflammatory disorders associated with abnormal Th2 
mediated responses, including some autoimmune diseases (115), asthma (161, 163), 
idiopathic pulmonary fibrosis(208), and sepsis(28); elevated sST2 levels are also 
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found in patients with other inflammatory conditions, like LPS-induced inflammation 
(162) and myocardial infarction (192). Additionally, sST2 has been proposed as a 
biomarker for heart failure (227). These findings suggest that increase in sST2 might 
reflect the development of inflammation and might play a role in its regulation. 
 
General Thesis Objectives 
The general objective of this thesis is to dissect the cellular response to 
dengue virus infection by studying its differential gene expression. We specifically 
studied the global gene expression response to DENV infection in vitro to identify 
and test gene function involved in major cellular events that might help to understand 
protective and/or immunopathological responses observed in DENV patients in vivo. 
We postulated that the global gene expression analysis approach to understand 
commonly regulated gene expression analysis in DENV-permissive cells would result 
in identification of genes / signaling pathways involved in inhibition of DENV 
spread. Endothelial cells are the primary target site for DENV infection-mediated 
pathogenesis. Hence, we reasoned that comparing endothelial cell response to DENV 
infection with infection by other RNA viruses that also affect endothelial cells might 
help us to identify factors that might represent, and allow future understanding of 
DENV infection mediated vascular dysfunction.  
Hence, we set out to identify whether (a) infection of DENV permissive cells 
(monocytes, B cells, HUVECs and dendritic cells) would activate type-I and type-II 
IFN activated antiviral molecule/s that inhibit DENV infection and replication (b) 
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infection of endothelial cells would activate DENV-specific genes when compared to 
other RNA viruses tested that also infect endothelial cells. 
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Chapter II 
  
Materials And Methods 
 
Isolation of primary human cells 
Blood samples were obtained from healthy U.S. volunteers at The University 
of Massachusetts Medical School. Monocytes and B cells were negatively selected 
from heparin-anticoagulated blood using a rosetting antibody precipitation kit 
(StemCell, Seattle, WA) and maintained in RPMI 1640 medium supplemented with 
10% fetal calf serum (FCS) and antibiotics. Sample purity was determined by cell 
surface staining of freshly isolated monocytes (CD14+, CD4-, CD8-, CD19-) and B 
cells (CD14-, CD4-, CD8-, CD19+).  
Primary HUVECs were obtained from pooled umbilical cords (two to five 
donor pools per culture). Human subject protocols were approved by Harvard 
University Medical School. HUVECs were maintained by the Core Facility of the 
Center for Excellence in Vascular Research at Harvard Medical School in M199 
medium supplemented with 10% FCS, 1 mM glutamine, endothelial cell growth 
stimulant, porcine intestinal heparin, and antibiotics. HUVEC cultures were split at a 
ratio of 1:3 or 1:4 for up to two passages. The protocol for preparation and passage of 
HUVECs is posted at http://vrd.bwh.harvard.edu/core_facilities/cx_huvec.html. For 
isolation of human monocyte-derived dendritic cells, CD14 microbeads (catalog 
number 120-000-305; Miltenyi Biotec) were used to positively select CD14-positive 
cells (monocytes) from Ficoll-isolated peripheral blood mononuclear cells from 
healthy donors. Monocytes (1.5 – 1.75 x 106 cells/ml) were cultured for 7 days in 
RPMI 1640 medium supplemented with 800 U/ml of granulocyte-macrophage 
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colony-stimulating factor, 500 U/ml of interleukin-4, and 10% FCS. Cells were 
stained for CD1a, CD14, HLA-DR, and CD83 on day 6 to determine the monocyte to 
immature DC conversion. 
 Cryopreserved muscle satellite cells were derived from muscle biopsies taken 
from the thigh muscle of healthy human donors and were donated by Mytogen, Inc 
(Charlestown, MA). The donor biopsies were obtained under an approved clinical 
study protocol (53). The donor identification protocol number was erased after cell 
preparation and culture of the satellite cells. Connective tissue was removed after the 
biopsy samples were placed in Ringer solution with heparin followed by 3 cycles of 
enzymatic digestion (0.5mg/ml Trypsin, 0.5mg/ml collagenase). The first cycle of 
enzymatic digestion was carried out for 60 min followed by two 40 min cycles. The 
temperature was maintained at 37oC and a total volume of 5ml of fresh digestion 
mixture was used for each cycle. The cells after each cycle of digestion were 
trypsinized and centrifuged in complete growth medium at 1000 r.p.m. for 5 min at 
40C. Cells were seeded in one T175 flask per digestion cycle. All cells were expanded 
for up to 10 – 12 doublings for purposes of optimizing yields and viability and then 
cryopreserved. The muscle satellite cells were thawed and formulated in DMEM + 
15% FCS (fetal calf serum), recombinant human epidermal growth factor (rhEGF:  
10 ng/mL), and dexamethasone (0.39 µg/mL) for growth. Muscle satellite cells at 
approximately 15 doublings were used for experiments in this study.  No myotubes 
were evident by microscopic inspection of the culture at the time of infection. The 
conditions described here are considered optimal for muscle satellite cell phenotype 
and survival for transplantation purposes (53). 
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 Virus Propagation 
Dengue virus was propagated as previously published (113). Briefly, C6/36 
cells were infected with low passage (passage 2-4) DENV at a multiplicity of 
infection (M.O.I.) of 0.1 and maintained in RPMI 1640 media containing xx% non-
essential amino acids, (concentration) sodium pyruvate, 10% FCS and (concentration) 
penicillin/streptomycin for approximately 7 days at 5% CO2 and 260C. Culture 
supernatants were collected after centrifugation and stored at –700C. DENV-infected 
C6/36 cell supernatants were titrated on Vero cells using the plaque assay technique. 
Uninfected C6/36 cell supernatants were collected for use as a negative control. 
 
Dengue Virus Infection:  
D2V New Guinea C (NGC), DENV1 Hawaii strain, D3V CH53489 and 
DENV4 strain 814669 of DENV were used for infection of primary human cells. 
D2V New Guinea C (NGC) is a laboratory-adapted prototype Southeast Asian D2V 
strain. All four dengue serotypes were obtained from Dr. Dubois (Yale University).  
 
(i) HUVECs 
HUVECs were obtained through collaborations with Dr. Sunil Shaw at 
Harvard University. Monolayers of HUVECs were resuspended in fresh cell culture 
medium. DENV strain New Guinea C (NGC) grown as described above was added to 
confluent monolayers of cells at a multiplicity of infection (MOI) of 0.5 to 1.5. Virus 
was allowed to adhere for 2 hours. The culture supernatant was then removed, and 
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fresh growth medium containing 10% FBS was added to each well. After 48 h of 
infection, cells were harvested, centrifuged at 700 x g for 7 min at 4°C, washed with 
phosphate-buffered saline (PBS), pelleted again at 700 x g for 7 min at 4 C, and 
stored at -70°C for analysis. 
 
(ii) Monocytes, B cells, PBMCs 
Monocytes/macrophages, B cells and PBMCs were obtained as described 
above. Cells were infected for 2-2.5 hours at 0.1 to 1 PFU/cell or cultured with 
uninfected C6/36 cell supernatant in RPMI medium containing 2% FCS at 37°C and 
5% CO2. After 2-2.5 hours, the medium was supplemented with FCS to bring the 
final concentration of FCS to 10% in the media. At the 48 hour timepoint cells were 
collected, washed and either stained for flow cytometry or cell pellets were stored at –
700C until use. Aliquots of the supernatant were kept at 70°C until use. 
 
(iii) DCs 
DCs were infected with DENV at a M.O.I of 0.1 for 2 hours at 37°C and then 
washed thoroughly, resuspended in RPMI 1640 supplemented with 10% FCS, 500 
U/ml of IL-4 and 800 U/ml of GM-CSF and incubated for 12, 24 or 48 hours. For 
TRAIL pre-treatment experiments, DCs were treated with 20 μg/ml of recombinant 
TRAIL (rTRAIL, Biomol International, PA) for 24 hours prior to infection. 
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(iv) Muscle satellite cells 
 Monolayers of muscle satellite cells maintained in fully supplemented 
medium were washed with fresh cell culture media with no FCS. DENV, previously 
grown in C6/36 cell monolayers and titrated in Vero cells, was added to confluent 
monolayers of muscle satellite cells at a multiplicity of infection (M.O.I) of 1-2. The 
cell culture supernatant was removed after two hours, the monolayers were carefully 
washed and fresh growth medium containing 10% FCS was added to each well.  
After 48 hours of infection, the culture supernatant was collected and stored at -70oC 
for plaque assay and ELISA. The cells were trypsinized and centrifuged at 700 x g for 
5 min (twice) and kept on ice for antibody staining or stored at –70oC for RNA 
extractions. 
 
Plaque Assay 
Cell culture supernatants from uninfected and DENV-infected cells were incubated 
with a monolayer of LLCMK2 cells for 2 hours with intermittent gentle mixing. Cell 
monolayers were washed with PBS and overlaid with medium viscosity carboxy 
methylcellulose (Sigma-Aldrich, St. Louis, MO). Carboxy methylcellulose was 
removed after 6 days by gently shaking the wells with 2ml PBS added to each well. 
The plate was washed four times with PBS. The washed cells were fixed and stained 
with 0.2% crystal violet in ethanol. Plaques were counted visually. Each sample was 
assayed in duplicate wells. 
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Recombinant Protein and Antibody Treatments 
(i) Antibody Treatment:  
Monocytes, B cells, and HUVECs were pretreated for 24 hours with TRAIL 
blocking monoclonal antibody (50 µg/ml; R&D Systems) or purified immunoglobulin 
G1 isotype control antibody (BD Biosciences) followed by infection with DV, as 
mentioned above, for 48 hours at an MOI of 1. The antibodies were left in the culture 
during the infection. The cells were collected by centrifugation at 500 x g, washed 
twice in phosphate-buffered saline (PBS), and cell pellets were stored at –70°C until 
analysis.  
(ii) Recombinant Protein Treatment:  
Monocytes were pre-treated for 24 hours with rTRAIL at concentrations from 
5 to 20 µg/ml (Merck, Germany) and infected with DENV at an MOI of 0.1. At 24 
and 48 hours post-infection, cells were washed twice with PBS and the cell pellets 
and supernatants were stored at –70°C. 
DCs were only pre-treated with rTRAIL (20 ng/ul, Biomol, PA) and infected 
with DENV at an MOI of 0.1. Two hours post-infection DCs were washed to remove 
residual virus used for infection and maintained in fresh RPMI 1640 medium 
containing 10% FCS, interleukin-4 (500 U/ml), and granulocyte-macrophage colony-
stimulating factor (800 U/ml). The media added post-infection was not supplemented 
with 20 µg/ml rTRAIL. 
DCs were pre-treated for 24 hours with rTRAIL (20 ng/ul, Biomol, PA) and / or 
IFNR blocking Ab (0.5-20 ng/ul) and infected with DENV at an MOI of 0.1 for 48 
hours. For the time-course of rTRAIL pre-treatment, DCs were treated for 24hour, 
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12-15hour, 30min or 0hour with rTRAIL (20 ng/ul, Biomol, PA) and infected with 
DENV at an MOI of 0.1 for 48 hours. DCs were washed at 2 hours post-infection to 
remove residual virus used for infection. Cells were maintained in fresh RPMI 1640 
medium containing 10% FCS, interleukin-4 (500 U/ml), and granulocyte-macrophage 
colony-stimulating factor (800 U/ml) till the end time-point of the experiment. At 
each time point, cells were stained for DENV antigen (DENV-fluorescein 
isothiocyanate), CD1a-allophycocyanin, HLA-DR-peridinin chlorophyll protein-
Cy5.5, and CD83-PE. Supernatants were stored at –70°C for future use. 
 
1-Methyl Tryptophan (1-MT) and IFNγ treatment  
 Dendritic cells were pre-treated with 500 U/ml of IFNγ or 500 U/ml of IFNγ 
and 0.1 or 1 mM 1-MT followed by infection with DV for 48hour at a M.O.I. of 1 as 
described above. 
The cells were collected by centrifugation for 5 min at 1,500 r.p.m., washed 
twice in PBS, and stored at -700C until analysis. RNA was extracted from the cell 
pellets using RNAeasy (Qiagen) and DENV RNA levels were quantified by TaqMan 
qRT-PCR.  
 
Affymetrix GeneChip hybridization and Analysis 
RNA isolated from DENV-infected, C6/36 treated and uninfected cells using 
the RNeasy kit (Qiagen) was biotin-labeled and hybridized to human oligonucleotide 
microarrays (Affymetrix HG-U133A) using standard methods as follows. First-strand 
cDNA was prepared by using a T7-(dT)24 primer and SuperScript II reverse 
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transcriptase (Invitrogen/Life Technologies) from 8 µg of total cellular RNA. Second 
strand synthesis was performed by using the Superscript Choice system 
(Invitrogen/Life Technologies), and the product was purified using a Qiagen PCR 
purification kit. Synthesis of biotin-labeled cDNA was carried out using a BioArray 
high-yield transcript labeling kit (Enzo), and cDNA product was purified by using 
RNAeasy kit (Qiagen). cDNA was fragmented and spiked with bacterial control 
genes (bioB, bioC, bioD, and cre) according to the Affymetrix protocol (ref manual). 
Hybridization to Affymetrix HG-U133A oligonucleotide microarrays (22,283 
genes) was carried out overnight with 10 µg of biotin-labeled cDNA product. 
Microarrays were washed using the GeneChip Fluidics Station (Affymetrix) 
according to the manufacturer's protocol. Staining with R-phycoerythrin-streptavidin 
(Molecular Probes) was followed by antibody amplification with a biotinylated 
streptavidin antibody (Vector Laboratories). Scanning was carried out using the 
GeneArray scanner (Hewlett-Packard). The data were collected with MAS5 software 
(Affymetrix) and analyzed using the Statistical Expression Algorithm to give signal 
values. Experiments displaying Affymetrix present call rates of >30% were included 
in the analysis. 
Signal values from each of the 22,283 probe sets were calculated using robust 
multiarray analysis (Irizarry RA,2003,4:249-264,Biostatistics). Signal values were 
transformed using the inverse natural log. For repeated experiments, inverse natural 
log-transformed robust multiarray analysis results were normalized based on the 
median and geometric means and were calculated prior to importing data into 
GeneSpring software (Agilent). Each GeneChip was independently normalized to the 
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median expression level of all genes on the chip. Each gene was then normalized to 
the median expression levels of that gene. Signals with low expression levels were 
excluded, and expression of statistical filters was applied as indicated. We analyzed 
our data by hierarchical cluster analysis using a Pearson correlation. Reproducibility 
was assessed as previously described (225). 
For the determination of the common response, the following analysis was 
performed: expression signals for 22,283 genes were filtered to exclude those with 
very low signals (2,000 genes), and the remaining genes were analyzed by one-way 
analysis of variance (ANOVA) to identify genes with statistically significant 
differences between DENV-infected samples (five samples) and uninfected samples 
(five samples). HUVECs (n = 2), monocytes (n = 2), and B cells (n = 1) represent 
cells exposed in vitro to DENV for 48 hours. The gene expression levels in DENV-
infected samples were normalized to C6/36 insect cell supernatant-treated samples for 
each cell type independently. For the determination of the DENV-specific response: 
expression profile for 22,283 genes were filtered to exclude those with low signals 
and remaining genes were analyzed by ANOVA to identify genes with statistically 
significant differences between DENV-infected HUVECs (n=2) and untreated 
HUVECs (n=4), HUVECs treated with C6/36 (n=1), poly I/C (n=1), HUVECs 
infected with other RNA [WNV (n=1), YFV (n=1), Hantaan (n=2), SNV (n=1)] and 
DNA [EBV (n=1), vaccinia (n=2)] viruses. Variances were calculated using the cross-
gene error model, parametric test, a P value cutoff 0.05, and the Benjamin and 
Hochberg false discovery rate multiple testing correction. For hierarchical cluster 
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analysis a Pearson correlation was used. n = number of independent experiments 
performed. 
 
Total RNA Extraction 
Total cellular RNA was extracted from as much as 2 x 107 uninfected or 
DENV-infected cells by using an RNA extraction RNAase column (Qiagen, Hilden, 
Germany). Typical yields were 10 µg of total RNA per million cells. Total RNA was 
digested with DNase I to eliminate residual DNA using the Message Clean Kit 
(GenHunter, Nashville, Tenn) when specified. The RNA was resuspended in diethyl 
pyrocarbonate-treated 0.01% distilled H2O (Ambion, Austin, Tex.) quantified by 
spectrophotometry (Bio Photometer, Eppendorf, Germany) at 260 nm and stored at -
80C until use. 
 
Quantitative RT-PCR  
(i) Semi-Quantitative RT-PCR:  
A total of 0.2 µg of total cellular RNA obtained from infected and uninfected cells 
cultures was reverse transcribed using Omniscript/SensiScript reverse transcriptase 
(Qiagen) in the presence of 1 µM anchor primer and a 500 µM dNTP concentration in 
a volume of 20 µl. RT was performed at 37°C for 60 min, followed by 94°C for 15 
min. PCR was performed with 0.5, 1, or 2 µl of cDNA. The 50-µl PCR included 2.5 U 
of Taq DNA polymerase (Clontech), 100 µM dNTP, and 100 µM of primers. PCR 
was run at 94°C for 1 min, followed by 25 cycles of 58°C for 1 min, 72°C for 45 s, 
and 94°C for 30 s, followed by 58°C for 1 min, and finally by 72°C for 10 min. L35a 
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(human ribosomal gene) was used as an endogenous control for all the experiments. 
Semi-quantitative RT-PCR Primer sequences specific to sST2 and ST2L isoforms of 
ST2 gene.  
sST2 - Forward Primer 5’AGGCTTTTCTCTGTTTCCAGTA 3’  
sST2 - Reverse Primer 5’ CAGTGACACAGAGGGAGTTCA 3’ 
ST2L - Forward Primer 5’AGGCTTTTCTCTGTTTCCAGT 3’ 
ST2L - Reverse Primer - 5’ GGCCTCAATCCAGAACATTTTT 3’ 
 
(ii) TaqMan Quantitation:  
RNA was extracted from the cell pellet using RNeasy (Qiagen) and subjected to 
TaqMan qRT-PCR for detection of TRAIL and DENV RNA. qRT-PCR of DENV 
RNA was performed as previously described (225). TRAIL mRNA was quantified 
using the same reaction conditions with TaqMan primer and probes obtained from 
Applied Biosystems. cDNA was obtained as described for semiquantitative analysis 
using 50-100 ng of total RNA, Taqman Reverse Transcription kit (Applied 
Biosystems) and oligo-dT primer. For PCR, we used a 25 or 50-µl reaction and 
Applied Biosystems (ABI) Universal 2X PCR Master Mix. A calibration curve 
containing five points ranging from 100 fg to 1 ng was used as a standard for the 
experiment, and L35a was used as an internal control for the unknown samples. 
Reactions were cycled at 50°C for 2 min and then 94.5°C for 10 min, followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min in the TaqMan PCR signal detection 
system 7300 (ABI). β-actin was used as an endogenous control for all the 
experiments. A standard curve was run using a precalibrated DENV sample for 
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absolute quantification of gene expression. Results were calculated using the standard 
curve method or relative quantification method using quantitative PCR software 
(Applied Biosystems). 
 
(iii) Microfluidic Cards:  
For microfluidic card analysis and qRT-PCR, total RNA was extracted from 
cells using a Qiagen RNeasy kit. RNA was subjected to 384-well microfluidic card 
(relative quantitation) analysis as described by the manufacturer (Applied 
Biosystems). One hundred nanograms of total cellular RNA was reverse transcribed 
using TaqMan reverse transcription reagents in the presence of random hexamers as 
primers. Reverse transcription was performed at 25°C for 10 min and 48°C for 30 
min, followed by 95°C for 5 min. For PCR, a 100-µl reaction mixture through a 
single port provided 2 µl of total reaction mixture per sample. The 100-µl PCR 
reaction mixture included 5 µl of cDNA, 45 µl of RNase/DNase-free water, and 50 µl 
of TaqMan Universal PCR Master Mix (2x). PCRs were cycled at 50°C for 2 min and 
94.5°C for 10 min, followed by 40 cycles of 97°C for 30 s and 59.7°C for 1 min in the 
PCR signal detection system 7900 (Applied Biosystems). β-actin and GAPDH were 
used as endogenous controls to equalize loading of total RNA between samples. Each 
data point was measured in quadruplicate, and the standard error was determined. 
 
Flow Cytometry 
Live cells were collected at the end of an experiment. 200,000 to 500,000 cells 
were aliquot to each tube and washed twice with 1ml of PBS. The cells were then 
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washed with FACS Buffer (2% FBS and 0.1% sodium azide in PBS) and stained with 
cell surface antibodies for 20 min at 40C in the dark. The surface stained cells were 
washed with FACS buffer and fixed and permeabilized with Cytofix / Cytoperm 
reagent (BD Pharmingen) for 20 min at 40C in the dark. The cells were then washed 
with Perm Wash solution (BD Pharmingen) and intracellular staining was performed 
for DENV (DENV 2H2 Ab conjugated to FITC, Chemicon, MA) or TRAIL (TRAIL-
PE) for 20 min at 40C in the dark. Stained cells were washed twice with FACS buffer 
and fixed in 0.5% paraformaldehyde in PBS and stored in the dark at 40C till the 
samples were run on FACsAria. Single color fluorescence compensation controls 
were performed for multi-color stained samples. Data were acquired on a FACsAria 
machine (BD Biosciences) and analyzed using FlowJo software version 6.0 or 8.6 
(TreeStar). Monocytes and DCs were stained for cell surface TRAIL using 
monoclonal anti-TRAIL-phycoerythrin (PE) antibody (BD Biosciences) and cell 
surface markers following the same surface staining protocol. The 2H2 Ab is a n 
antibody to PrM which recognizes the mouse anti-dengue virus complex monoclonal 
antibody (99). 
 
Detection of apoptosis in DCs 
(i) Poly(ADP-ribose) polymerase 1 (PARP-1) protein cleavage detection 
Cells undergoing apoptosis cleave PARP-1 protein (116-kDa) into two smaller 
fragments (85 and 25 kDa) (110). PARP-1 protein cleavage is the last known stage in 
cell death to differentiate between apoptosis and necrosis. DCs infected with DENV 
for 48 hours were washed twice with PBS and stained with PARP-1-PE antibody (BD 
  39
Biosciences) followed by flow cytometry analysis. 
(ii) Caspase-3 and Live/Dead Aqua stain 
Live/Dead Aqua stains dying cells while active caspase-3 is an early marker 
for cells undergoing apoptosis (66). DENV-infected DCs either untreated or treated 
with TRAIL were stained for apoptosis using caspase-3 and Live/Dead Aqua dye at 
12, 24, and 48 hours postinfection. DCs incubated in a 65°C water bath for 20 min 
and camptothecin B (2 mM)-treated THP-1 cells were used as positive controls for 
Live/Dead Aqua staining. DCs treated with camptothecin B (2 mM/ml) for 4 hours 
were used as a positive control for caspase-3 staining. Cells were stained using the 
protocol described above. 
 
Intracellular Cytokine Staining (ICS) 
DCs were infected with DENV as described above at a multiplicity of 
infection (M.O.I.) of 0.1 for 12, 24, and 48 hours. Cells were treated with brefeldin A 
for the last 8 hours of each time point to inhibit secretion of proteins. At the end of 
each timepoint cells were collected, washed and cells were surface stained for DC 
markers (CD1a+ CD14–) and total (surface and intracellular) TRAIL protein using 
monoclonal anti-TRAIL-phycoerythrin (PE) antibody (BD Biosciences).  
 
Quantification of Proteins in Cell lysates, Serum or Culture Supernatants 
Commercial ELISA assays were used to measure levels of TRAIL (R&D Systems), 
sST2, MCP-2, IP-10, IL-6, ITAC and IFNα (Ray Biotech Inc., R&D Systems) in 
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monocytes cell lysates, DC culture supernatants, or sera, following the 
manufacturers’ instructions.  
 
Mass-Spectrometry 
Standard and Sample Preparation: 
Prism RP 100x1.5um was used for delivery of the mobile phases A (2% Acetonitrile, 
2% Formic acid), B (40% Acetonitrile, 2% Formic acid). 
Serum concentrations of Tryptophan and kynurenine were measured using reverse-
phase HPLC. Frozen sera were thawed at room temperature. Sera were deproteinized 
by adding 1/10 (v/v) of 2.4 M perchloric acid. The sera were vortexed and centrifuged 
for 5 min at 3500g and 40C. The supernatant was pipetted into another tube and 6% 
trichloroacetic acid (TCA) was added and the tube was mixed well (vortex) to obtain 
a final concentration of 1% (w/v) TCA. The tube was centrifuged at 14,000 r.p.m. for 
5 min at 40C. The sample was directly injected into the separation column. The 
samples were stored at -200C in the dark for later use. 
 
Statistical Analysis: The SPSS 15.0 software was used for statistical analysis. Due to 
the small sample size, and a non-Gaussian pattern of sample values, a non-parametric 
method (Mann-Whitney test) was used to compare groups. 
 
Clinical Samples from collaborators. 
Dengue clinical samples were obtained from clinical cases by collaborations 
with other researchers. The patients were defined following the World Health 
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Organization (WHO) guidelines (1). Diagnostics of dengue patients were done 
virologically, by detection of DENV serotype-specific reverse transcription and 
polymerase chain reaction (RT-PCR) was performed using the One-step PCR kit 
(QIAGEN) and primers described in Lanciotti et al. (119) adapted to a one-step RT-
PCR, using reverse primer and serotype specific forward primers. Dengue patients 
were also described by clinical signs and symptoms, hematological and liver 
functionality tests and coagulation tests. Becerra et al. 2008 has more complete 
description of the cohort used in Chapter IV. Serologic studies were also conducted in 
the patient samples. Dengue antibodies were measured in paired enrollment and 
convalescence sample, using IgM-ELISA and hemagglutination inhibition assay (HI), 
at the Instituto Nacional de Higiene Rafael Rangel, Caracas, Venezuela. Patients were 
classified as Dengue or as an Other Febrile Illness (OFI) based on the detection of 
dengue RNA, presence of IgM antibodies and / or at least a four-fold increase in HI 
levels in S2 compared to S1. The HI levels were used to further classify dengue 
patients as a primary infection (HI titer ≤ 1:1280) or secondary infection (HI titer > 
1:1280).  
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Chapter III 
Identification of the cellular response of primary human cells to dengue virus 
(DENV) infection 
The first objective of this section of the thesis was to utilize global gene 
expression analysis to identify genes involved in the cellular response to DENV 
infection and also to propose proteins markers that can help identify DENV infection 
from other viruses. We utilized an in vitro DENV infection model to identify genes 
with potential antiviral or biomarker function. DENV-susceptible primary human 
cells, including monocytes, B cells and HUVECs, were exposed to DENV, in vitro. 
Finally, we investigated a novel primary human cell type, muscle satellite cells, to 
evaluate their susceptibility and responses to DENV infection. 
 
Source and Purity of primary human cells  
We first assessed the purity of monocytes and B cells isolated from blood of 
healthy US donors using commercially available negative selection kits (RosetteSep, 
StemCell). Monocytes (Mo) and B cells isolated from blood were ~79% CD14+ and 
~87% CD19+, respectively (Table 1). These data indicate that the majority of the cells 
isolated using the negative selection protocol were either CD14+ or CD19+ for the 
monocytes and B cell isolation kit, respectively. We detected very low percentage of 
CD4+, CD8+ and CD19+ cells or CD4+, CD8+ and CD14+ cells using the B cell and 
monocyte negative isolation kit, respectively (Table 1).  
Monocytes were converted into dendritic cells (monocyte-derived DCs, DCs) 
using the protocol mentioned in detail in Chapter II. On average, by the 6th day of  
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Table 1: Purity of primary monocytes, B cells isolated from healthy donor blood and 
percent conversion of monocytes to dendritic cells (DCs) as analyzed by FACS. 
 
 
 
Cell Type Mean Percent +/- SE
B cells (N=5)
CD19+ 86.4 +/- 2.078
Surface Markers CD14+ 1.8 +/-0.41
CD4+ 0.8 +/- 0.051
CD8+ 0.3 +/- 0.19
Monocytes (N=5)
CD19+ 1.0 +/- 0.447
Surface Markers CD14+ 78.3 +/- 0.87
CD4+ 1.0 +/- 0.179
CD8+ 0.3 +/- 0.224
Dendritic Cells (N=10)
Surface Markers CD83+ 0.45 +/- 0.12
CD1a+ 80.34 +/- 3.98  
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culture, 60-91% of monocytes were converted to DCs (CD1a+ cells) (Table 1). The 
CD1a+ cells were stained for CD83 on the 6th day of culture to confirm that the DCs 
were immature. For all donors, very few (<1%) CD1a+ cells stained positive for CD83 
surface antigen (Table 1).  A good generation of immature DCs (CD1a+, CD14- and 
CD83-) from monocytes was also observed using our cell culture protocol (Chapter 
II). DCs also expressed high level of HLA-DR protein.  
HUVECs were obtained from the Core Facility of the Center for Excellence in 
Vascular Research at Harvard Medical School. The detailed purification procedure is 
described at (http://vrd.bwh.harvard.edu/core_facilities/mlec.html).  
 
III.1. Identification of common gene expression response following DENV 
infection of HUVECs, B cells and Mo in vitro  
Innate immune response [type-I IFN and type-II IFN] is considered important 
in limiting DENV spread based on studies in mice and human cells, in vitro (51, 52, 
194, 196). Since, innate immune response is activated in a wide variety of cells in 
vivo on exposure to pathogens, we hypothesized that cells susceptible to DENV 
infection might limit DENV replication and spread by inducing a common innate 
immune response. To identify common gene expression changes in primary human 
cells in response to DENV infection, we analyzed the transcriptome of the infected 
cells by global gene expression profile in HUVECs, monocytes and B cells using 
Affymetrix GeneChip arrays. These cell types are known to be susceptible to DENV 
infection in vitro and have been reported to show evidence of infection during DENV 
infection in vivo. All the cells tested were infected with DENV  
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Figure 1A. Gene expression analysis using HG-U133A Affymetrix GeneChips. 
Expression levels for the 23 DENV common response genes in cells exposed to 
DENV. HUVECs (n = 2), monocytes (n = 2), and B cells (n = 1) represent cells 
exposed in vitro to DENV for 48 hours. In vitro infection profiles were normalized to 
C6/36 insect cell supernatant-treated samples for each cell type independently. 
Hierarchical cluster analysis used a Pearson correlation. Color indicates relative 
changes in induction (n-fold). On the color scale, dark red represents 20-fold up-
regulation, white indicates no change and blue indicates down-regulation. Affymetrix 
microarray analysis was performed using GeneSpring software (Agilent). 
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Figure 1B. Comparison of gene expression analysis in DENV-infected HepG2 cells 
to expression in primary human cells. Monocytes (n=2), B cells (n=1), HUVECs 
(n=2) and DCs (n=2). This figure shows the expression levels of the 79 common 
response genes (monocytes, B cells, HUVECs and DCs) to expression in HepG2 
(Hep) cells exposed to DENV, in vitro. Hep stands for HepG2 cells. Numbers at 
bottom indicate the percentage of genes that were induced at least 2.5-fold. n 
represents number of independent experiments. Hierarchical cluster analysis used a 
Pearson correlation. Color indicates relative changes in induction (n-fold). On the 
color scale, dark red represents 20-fold up-regulation, white indicates no change and 
blue indicates down-regulation. Affymetrix microarray analysis was performed using 
GeneSpring software (Agilent). Box – Expression of TNFSF10 (TRAIL) in DENV-
infected primary cells and HepG2 cell line.  
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propagated in C6/36 mosquito cells. Control samples were mock infected with 
uninfected C6/36 supernatants.  
Of the 23 genes that comprised the common dengue response profile, functions 
and/or descriptions of 19 genes have been found in the literature (Table 2). Figure 1A 
shows 27 genes in the list of 23 different genes due to repetition of OASL, IFITM1, 
ISG20 and TRAIL in the analysis output. These include classical anti-viral response 
genes (OAS3 and IRF7), more recently identified anti-viral genes (ISG15, HERC5, 
RSAD2, TRIM5, TRAIL, OASL, ISG20), genes regulating ubiquitination (USP18), 
cell adhesion and cyclic ADP-ribose (cADPR) metabolism (CD38), apoptosis 
(XAF1), immune suppression (IFITM1), immune activation (LGALs3BP), anti-
proliferative (SAMD9) and eight other genes (FLJ20035, FLJ38348, HERC6, IFI44, 
IFI44L, IFIT1, IFIT3, LY6E) currently with unknown function. 
 Gene expression analysis of DENV-infected HepG2 cells showed a very 
different pattern of expression for genes as compared to DENV-infected primary 
(monocytes, B cells, HUVECs and DCs) cells (Figure 1B). TRAIL (TNFSF10), the 
gene identified as the potential common linker from DENV-infection of primary cells 
(Figure 2) was not induced in HepG2 cells (Figure 1B box). This data indicates that 
primary cells might be better model to understand changes in expression of cellular 
genes following DENV infection.  
 
Validation of the differential expression of the common response genes 
ANOVA identified a set of 23 transcripts that demonstrated a significant 
change in expression (P of <0.05) in all cell types studied (Fig. 1A and Table 2). To  
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 Table 2. Biological functions of the 23 DENV response genes 
 
Name Functional Category Description GenBank Affy ID
G1P2 Anti-viral Interferon, alpha-inducible protein (clone IFI-15K) NM_005101 205483_s_at
IRF7 Anti-viral Interferon regulatory factor 7 NM_004030 208436_s_at
ISG20 Anti-viral Interferon stimulated gene 20kDa NM_002201 204698_at
OAS3 Anti-viral 2'-5'-oligoadenylate synthetase 3, 100kDa NM_006187 218400_at
OASL Anti-viral 2'-5'-oligoadenylate synthetase-like NM_003733 205660_at
RSAD2 Anti-viral Radical S-adenosyl methionine domain containing 2 AI337069 213797_at
TRIM5 Anti-viral Tripartite motif-containing 5 AF220028 210705_s_at
HSXIAPAF1 Apoptosis XIAP associated factor-1 NM_017523 206133_at
TNFSF10 Apoptosis Tumor necrosis factor (ligand) superfamily, member 10 U57059 202687_s_at
CD38 Cyclic ADP-ribose metabolism CD38 antigen (p45) NM_001775 205692_s_at
HERC5 HECT E3 Ubiquitin ligase Hect domain and RLD 5 NM_016323 219863_at
IFI44 Interferon-Inducible Interferon-induced protein 44 NM_006417 214453_s_at
IFI44L Interferon-Inducible Interferon-induced protein 44 NM_006820 204439_at
IFITM1 Immune suppression Interferon induced transmembrane protein 1 (9-27) AA749101 214022_s_at
LGALS3BP Immune Activation Lectin, galactoside-binding, soluble, 3 binding protein NM_005567 200923_at
USP18 Ubiquitination Ubiquitin specific protease 18 NM_017414 219211_at
SAMD9 Anti-proliferative Sterile alpha motif domain containing 9 NM_017654 219691_at
FLJ20035 unknown Hypothetical protein FLJ20035 NM_017631 218986_s_at
FLJ38348 unknown Hypothetical protein FLJ38348 AV755522 213294_at
HERC6 unknown Hect domain and RLD 6 NM_017912 219352_at
IFIT1 unknown Interferon-induced protein with tetratricopeptide repeats 1 NM_001548 203153_at
IFIT3 unknown Interferon-induced protein with tetratricopeptide repeats 3 NM_001549 204747_at
LY6E unknown Lymphocyte antigen 6 complex, locus E NM_002346 202145_at  
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confirm the gene expression changes detected by Affymetrix GeneChip, 11 genes for 
which primers and probes were available were selected for validation by qRT-PCR. 
qRT-PCR confirmed up-regulation (greater than threefold) of all the 11 genes 
in DENV-infected HUVECs and monocytes (Table 3). Also, the qRT-PCR and 
GeneChip results for gene expression were consistent for HUVECs (Table 4). 
 
Identification of TRAIL as a common linker of the common response genes  
To identify signaling pathways associated with the host cell response to DENV 
infection, we analyzed our common response gene list using Pathway Architect 
software (Stratagene).  
This analysis found the commonly regulated genes to be predominantly 
regulated by type-I IFN (IFNα/β) and type-II IFN (IFNγ) signaling pathways (Figure 
2). In addition, TRAIL/TNFSF10, one of the 23 common response genes, was 
identified as a potential linker of these two signaling pathways. 
 
III.2: Identification of the gene expression response specific for DENV infection 
of HUVECs in vitro 
Endothelial cells are targets for DENV infection based on in vitro and in vivo 
studies. In addition, vascular dysfunction is considered the reason for plasma leakage, 
vascular permeability and bleeding; clinically symptoms detected during DENV 
infection-mediated pathogenesis (DHF/DSS).  Hence, we used the in vitro endothelial 
cell model for infection with DENV and other RNA viruses in an effort to detect 
DENV infection-specific responses.  
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 Genes qRT-PCR Fold Induction
Monocytes HUVECs
C1orf29 12 31
CEB1 9 6
G1P2 8 15
HSXIAPAF1 2 8
IF144 23 10
IF1T1 6 32
IRF7 6 24342
ISG20 13 3
LGALS3BP 11 15
LY6E 17 4
USP18 37 5  
Table 3. qRT-PCR validation of the 11 DENV response gene. In vitro DENV 
infections in HUVECs were analyzed by qRT-PCR using microfluidic cards. Relative 
induction was calculated with qRT-PCR software (Applied Biosystems). The qRT-
PCR and GeneChip results showed similar fold induction for HUVECs and 
monocytes. 
 
 
 
 
Gene Name GeneChip PCR
Fold Induction Fold Induction
ISG20 15 3
LYE6E 8 4
USP18 14 5
HERC5 9 6
HSXIAPAF1 7 8
IFI44 27 10
G1P2 28 15
LGALS3BP 3 15
IFI44L 58 31
IFIT1 126 32
IRF7 12 >100
 
 
 
 
 
 
 
 
 
TABLE 4.GeneChip and PCR expression comparison of the common response 
genes. In vitro DENV infections in HUVECs were analyzed by GeneChip and qRT-
PCR analysis. Relative induction was calculated with qRT-PCR software (Applied 
Biosystems). 
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Figure 2. TRAIL is potential linker of the majority of the common response genes.  
The software used generated a Biological Association Network (BAN) of known 
protein interactions using a proprietary database containing over 140,000 references 
that are updated automatically on protein interactions obtained from PubMed (NCBI, 
NIH). The software was set up to identify and display common putative regulator(s) 
of the common response genes. 
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We selected RNA viruses (WNV, YFV, Hantaan and SNV) to control for 
immune response and antiviral genes which might be induced commonly in response 
to infection with RNA viruses. DNA viruses (vaccinia and EBV) were used as 
controls for non-specific viral responses. Among the RNA viruses, YFV and SNV, 
which are also hemorrhagic fever viruses, were used as controls to identify cellular 
responses that might be involved in regulation or induction of pathology 
(hemorrhage) during DENV infection. We wanted to infect HUVECs with DENV 
and other viruses at a dose which might be close to the physiologically relevant dose 
of infection. Hence, HUVECs were exposed to all the viruses at M.O.I. of 1. We 
performed qRT-PCR for DENV, WNV, YFV or Hantaan in virus-infected HUVECs 
to determine if these viruses were able to replicate in HUVECs. 
Among the Gene expression analysis of DENV, other RNA viruses and DNA 
viruses identified 30 genes that were potentially differentially regulated specifically in 
DENV-infected HUVECs (Fig. 3). Some of the genes listed include C1S (classic 
complement), kynureninase (kynurenine pathway of L-Trp degradation), SOD2 
(protects mitochondria from oxidative stress damage) (174), CARP, IL-1β (pro-
inflammatory cytokine), IL8, cathepsin S, TNFSF4 (OX40L) implicated in Th2 
priming to Th cells (91), DTR, IL1rL1, tenascin C, SCYB5 (epithelial-derived 
neutrophil activating, ENA-78) (87), ATP binding protein regulating calcium influx 
(P2RX4) (232). 
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Figure 3. DENV-specific gene expression analysis using HG-U133A Affymetrix 
GeneChips. Expression levels for the 30 DENV-specific genes in HUVECs exposed 
for 48 hours to DENV, other RNA viruses or DNA viruses known to infect HUVECs. 
In vitro infection profiles were normalized to C6/36 insect cell supernatant-treated 
samples or culture media for each cell type independently. Hierarchical cluster 
analysis used a Pearson correlation. Color indicates relative changes in induction (n-
fold). On the color scale, dark red represents 20-fold up-regulation, and white 
indicates no change. Affymetrix microarray analysis was performed using 
GeneSpring software (Agilent). Each lane in the figure is an independent experiment. 
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Confirmation of the DENV-specific gene expression analysis 
We confirmed an increase in expression for 6 potential DENV-specific response 
genes to infection of HUVECs and monocytes with DENV in vitro. Kynureninase 
was among the list of genes specifically induced in response to DENV infection in 
HUVECs. Kynureninase enzyme regulates a downstream step in the production of 
NAD+ from tryptophan. In literature, studies have focused on the first which is the 
rate limiting step of the kynurenine pathway of tryptophan degradation. IDO enzyme 
regulates that initial and rate-limiting step of the tryptophan catabolism pathway.  
IDO has shown to play a role in T cell proliferation and peripheral tolerance (150, 
151). Also, previous studies have found IDO activity to be important for IFNγ 
mediated antiviral function for viruses (4, 160). Hence, we focused on IDO qRT-PCR 
expression levels. qRT-PCR analysis confirmed DENV infection induced gene 
expression levels suggested by Affymetrix analysis (Table 5).  
 To determine their expression in patient samples we further confirmed 
specificity of the differential regulation of these genes in PBMCs obtained from 
DENV (n=3) and OFI (n=1) patients during febrile phase of the infection (data not 
shown). The preliminary comparison with OFI patient PBMCs was done to control 
for non-specific activation of these genes due to febrile (most likely viral) illness. 
 We found that IDO and ST2 gene mRNA were expressed at much higher 
levels in DENV patient PBMCs as compared to in OFI patient PBMCs (data not 
shown). Hence, we have identified two potential DENV infection specific genes 
using genomic analysis of in vitro DENV-infected HUVECs.  
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Table 5: Confirmation of 7 DENV response genes in HUVECs. Relative induction 
was calculated with qRT-PCR software (Applied Biosystems). qRT-PCR confirmed 
induction of the genes following DENV-infection suggested by the GeneChip results 
in the HUVECs for 4 out of the 7 genes. 
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Expression levels of seven DENV infection inducible genes were validated by qRT-
PCR. 
 
III.3. Investigation of the Susceptibility of Muscle Satellite Cells to DENV 
 
 The cause of myalgia during DENV infection is still unknown. One possible 
hypothesis for the myalgia and musculoskeletal pain frequently observed during 
DENV infection is that muscle cells are infected by DENV. Muscle satellite cells are 
precursor skeletal muscle cells. Satellite cells are resident, proliferative cells found in 
the skeletal muscle. These cells express muscle specific markers like neural adhesion 
molecule (NCAM) or CD56 and Desmin (19, 72) and will spontaneously fuse to form 
mature, contractile, skeletal muscle. In addition, they their proliferative capacity 
makes them an ideal model for in vitro infection studies on skeletal muscle. Hence, to 
determine whether DENV can infect primary muscle cells, we exposed human muscle 
satellite cells to DENV in vitro.  
Purity of muscle satellite cells 
 Desmin and CD56 are both considered reliable markers for muscle satellite 
cells among cells cultured from skeletal muscle (165, 204, 239). Fibroblasts, which 
co-propagate in cell culture, do not express CD56 (6). Hence, we used CD56 as a 
marker to determine the purity of muscle satellite cells cultured in vitro. 
Approximately 15-30% of the live gated cells did not stain positive for CD56 (Fig. 4). 
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DENV can infect and produce infectious progeny in muscle satellite cells 
 
 To determine whether these cells could serve as a host for DENV infection, we 
exposed them to DENV in vitro and determined their susceptibility to a productive 
DENV infection. 
 Primary human muscle satellite cells were infected with DENV2 strain New 
Guinea C (NGC), DENV1 strain Hawaii, DENV4 strain 814669 at M.O.I. of 2, for 24 
and 48 hours and stained for DENV antigen. Similar proportions of muscle satellite 
cells stained positive for DENV2 antigen at the 24 hour (16.9±4.2%, n=3) and 48 
hour (9.5±3.4%, n=3) time-points (Fig. 5A and 5B). Since DENV2 NGC represents a 
prototype strain of DENV we investigated whether DENV1 and DENV4 strains could 
also productively infect muscle satellite cells. 
 Muscle satellite cells also stained positive for DENV1 (6.6±2.7%, n=2) and 
DENV4 (21.5±12.3%, n=2) antigens (Fig. 5B) at levels comparable to DENV2 as 
determined by flow cytometry. These results demonstrate that muscle satellite cells 
are susceptible to infection with multiple DENV serotypes, in vitro. 
We also demonstrated the direct presence of DENV antigen in muscle satellite 
cells using immunofluorescence microscopy. Cells were grown on microscope cover 
slips overnight and then infected with DENV2 at an MOI of 2. After 48 hours, cells 
were fixed and stained for DENV and desmin. Desmin and DAPI double-positive 
cells clearly stained positive for DENV antigen in the cytoplasm (Fig. 6). 
 To determine whether DENV-infected muscle satellite cells produced infectious 
DENV progeny we performed plaque assay on DENV-infected muscle satellite cell 
supernatants. High levels of infectious DENV progeny (104-106 pfu/ml) were
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Figure 4. Gating of live cells and CD56-positive population. Forward scatter  
(FS) and side scatter (SS) plot was used to initially gate on live cells. Next the live 
gated cells were gated on CD56 Ab to select the muscle satellite cells for further flow 
cytometry analysis. 
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Figure 5. Detection of dengue virus (DENV) in primary human muscle satellite cells 
by flow cytometry. (A) Primary muscle satellite cells obtained from three donors 
were infected with DENV2 for 48 hours at M.O.I. of 2. Both uninfected and DENV-
infected cells were stained with anti-DENV-FITC (Chemicon). (B) Primary muscle 
satellite cells obtained from two donors were infected with DENV1, DENV2 and 
DENV4 for 24 hours at M.O.I. of 2. Each infection was performed in duplicate. 
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Figure 6. Immunofluorescence microscopy of muscle satellite cells using 20X 
objective.  (A-D) Nuclei are visualized using DAPI staining, which is shown in blue 
in all four images.  A and B represent uninfected cells. A, desmin (red).  B, dengue 
(green) localization absent. C and D represent cells infected with DENV at MOI of 2: 
C, desmin (red) is seen in all four cells within the field of view.  D, all four muscle 
satellite cells are positively stained with anti-dengue antibody (green) indicating 
DENV infection. 
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detected in the supernatant from both DENV2- and DENV4-infected muscle satellite 
cells by plaque assays (Fig. 7). 
 
Chapter Summary 
One aim of this section of the thesis was to apply gene expression analysis of 
multiple DENV-infected primary human cell types to identify genes of interest for 
further study. We applied a two pronged approach for identification of genes of 
significance for regulation or identification of DENV infection. 
 The common gene expression profile of 23 genes detected in DENV-infected 
monocytes, B cells and HUVECs identified TRAIL, one of the common response 
genes, as a potential common linker of the type-I and type-II IFN response genes 
(PathwayArchitect, Stratagene). In addition, we identified potential endothelial cell 
DENV infection-specific response genes in HUVECs infected in vitro. Among the 
DENV-specific response genes confirmed in PBMCs from acute phase of the disease 
in OFI and DENV patients we identified ST2 and IDO genes as potential biomarkers 
for DENV infection.   
 Another aim of this section of the thesis was to determine the capacity of 
DENV to infect primary muscle satellite cells. Flow cytometry analysis and 
immunofluorescence microscopy experiments showed that DENV can infect primary 
muscle satellite cells. Further, large amounts of infectious DENV progeny were 
released by primary muscle satellite cell cultures as detected by plaque assay.   
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Figure 7. Muscle satellite cells produce infectious DENV progeny. Muscle satellite 
cells were infected with DENV for 0, 24 and 48 hours at M.O.I. of 2. At each time 
point plaque assay was performed to determine infectious DENV progeny. 
Experiments performed for DENV2 infection at zero hour (n=4), 24 hour (n=3) and 
48 hour (n=5). Experiments performed for DENV4 infection at zero hour (n=2) and 
24 hour (n=2). 
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Chapter IV 
TRAIL is involved in the antiviral and the anti-inflammatory response of 
primary human cells to DENV infection  
The common gene expression profile data from Chapter III identified TRAIL 
as a potential common linker of the type-I and type-II IFN-inducible genes. TRAIL, a 
member of the TNF superfamily, has been shown in previous studies to have antiviral 
and anti-tumor activity(22, 26, 102, 133, 171, 184, 187, 220, 223, 238). TRAIL 
exhibits potent antiviral activity against influenza, CMV and other viruses (22) (89, 
188). In addition, Secchiero et al. has shown that TRAIL can inhibit the adhesion of 
leukocytes to TNFα- and IL1β- activated HUVECs and HAECs (185). 
 Hence, in this section of the thesis we determined the pattern of expression of 
TRAIL following DENV infection and whether TRAIL played a role in regulating 
DENV infection and pro-inflammatory genes in primary human cells.   
  
TRAIL mRNA induction in DCs, Mo and B cells 
In Chapter III, we observed that the expression of TRAIL mRNA was induced 
in DENV-infected primary human cells. Using real-time PCR, we determined TRAIL 
mRNA expression levels in monocytes, B cells and DCs infected with DENV, in 
vitro. TRAIL mRNA was induced in DENV-infected monocytes, B cells, and DCs 
(Fig. 8). The induction of TRAIL mRNA was similar in all the cell types tested. 
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Figure 8. TRAIL mRNA induction in DENV-infected cells. Monocytes, B cells, and 
DCs were infected with DENV at MOI of 0.1 and / or 1 PFU/ml for 48 hours. TRAIL 
mRNA expression was quantified by qRT-PCR on total RNA extracts. β-actin mRNA 
was used as a control probe. Data shown are representative of multiple (N) 
independent experiments. 
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TRAIL protein is produced by DENV-infected cells 
 Cells can regulate protein levels through other mechanisms and mRNA levels 
may not reflect protein levels (13, 15, 128, 144). Hence, we wanted to confirm that 
DENV infection induced an increase in TRAIL protein levels. TRAIL protein is 
capable of initiating its function through the engagement of its death receptors, 
TRAIL-R1 (DR4) and TRAIL-R2 (DR5) (44). Previous studies have shown that 
TRAIL protein can be secreted by the cell or localize inside (cytoplasm) or on the 
surface of the cell (56, 147, 224). 
Initially, we determined whether TRAIL expression was induced at the 
protein level in cell culture supernatants and cell lysates from DENV-infected 
monocytes and cell culture supernatants from DENV-infected DCs. Monocytes and 
DCs are the most accepted cellular targets for DENV infection and replication, in 
vivo. No TRAIL protein was detected in the supernatant of DENV-infected 
monocytes and DCs by ELISA, most likely due to the small amounts of TRAIL 
present at the timepoint when the assay was performed and at the amount of cells in 
the culture (one million cells per ml at 0.1 MOI for 48 hours of infection). However, 
we detected larger amounts of TRAIL protein, 180.93 ± 101.9 pg/ml (mean ± 
standard deviation [SD]; n = 3), in DENV-infected monocyte cell lysates compared to 
uninfected monocyte lysate at 48 hours after infection with DENV in vitro at 1 MOI 
(Fig. 9A). TRAIL protein levels were below the level of detection (ELISA) in 
uninfected monocytes. These results indicated that TRAIL protein is localized inside 
the cell or on the surface of cells following DENV infection. 
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Figure 9. Intracellular TRAIL protein levels were measured (A) in cell lysates by 
ELISA, and (B) by intracellular staining. (A) Monocytes (Mo) were infected with 
DENV at an MOI of 1 PFU/cell and then cultured for 48 hours. Levels of TRAIL 
protein were quantified in cell lysates using ELISA (R&D Systems). Data shown are 
representative of three experiments. (B) DCs were infected with DENV for 12, 24, 
and 48 h at an MOI of 0.1. Cells were treated with brefeldin A for the last 8 h of each 
time point. TRAIL protein was detected by flow cytometry using TRAIL-PE (BD 
Biosciences). DENV antigen was stained using the DENV-FITC Ab (2H2 Ab). Data 
shown are representative of two experiments.   
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In vitro, DENV-infected primary human monocytes do not stain well for 
DENV antigen unlike DENV-infected monocyte derived dendritic cells, which stain 
clearly for DENV antigen. Hence, to determine whether DENV-infected or bystander 
(uninfected) cells of the same culture flask were able to express TRAIL, we analyzed 
DENV-infected DCs by flow cytometry. We did not detect TRAIL protein on the 
surface of DENV-infected monocytes and DCs (data not shown), suggesting that 
TRAIL protein detected in DENV-infected cells was localized inside the cell. Hence, 
we performed intracellular staining assay on DENV-infected DCs to identify the cells 
producing TRAIL protein following DENV infection.  
Increased intracellular TRAIL protein was detected at 12 hours but the TRAIL 
protein levels decreased to much lower levels by the 24- or 48-hour time points after 
infection, with less than 2% of the cells expressing TRAIL (Fig. 9B). However, we 
could not detect DENV antigen expression at the 12 hour timepoint postinfection. 
Hence, we cannot conclude whether TRAIL was expressed in DENV-infected or 
uninfected (bystander) cells or both. The lack of TRAIL detection at 24 and 48 hour 
post-infection indicates that TRAIL expression is transient in DCs. Very few DCs 
were positive for DENV antigen at the 12 hour timepoint postinfection when the 
TRAIL protein levels were high. One possible explanation for this finding is that, 
since TRAIL is an early expressed gene, it is possibly an upstream regulator of 
cellular DENV response.  
The DENV antigen-positive cells did not express TRAIL protein. An 
explanation for this finding is that DENV infection might inhibit expression of 
TRAIL protein. TRAIL has previously been shown to function as an antiviral 
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molecule against CMV, ECMV, influenza and other viruses (89, 184). Thus, these 
data lead us to speculate that DENV might block TRAIL expression to suppress the 
antiviral response against DENV. 
In summary, DENV infection induced TRAIL protein in cells was both 
transient and early, 12 hours postinfection. 
 
TRAIL functions as an antiviral molecule against DENV 
(A) Blocking of endogenous TRAIL enhances DENV replication in vitro 
To determine if TRAIL produced in response to DENV infection was 
involved in the antiviral response against DENV, we determined the effect of TRAIL 
neutralizing antibody (Catalog# 550912, BD Biosciences) on DENV levels in 
infected cells. IFNα is a strong inducer of soluble and cell surface expression of 
TRAIL in monocytes and B cells (56). Since we were using primary monocytes and 
B cells to determine the effect of blocking TRAIL protein on DENV levels, the 
IFNα-mediated increase in TRAIL expression was utilized to titrate the TRAIL 
neutralizing antibody. Titration of TRAIL neutralizing antibody was performed 
against IFNα (100 U/ml) treatment in primary monocytes to determine the 
concentration of the antibody required to neutralize the surface bound TRAIL protein 
(56). The titration experiment found that the anti-TRAIL Ab at 50ug/ml concentration 
was able to block binding of the fluorescent Ab to all surface bound TRAIL protein 
(data not shown). TRAIL neutralizing antibody at the titrated concentration was used 
to block TRAIL function in DENV-infected monocytes, B cells, and HUVECs.  
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Figure 10. TRAIL blocking monoclonal antibody increases DENV replication. 
Monocytes, B cells, and HUVECs were infected with DENV at an MOI of 1 PFU/cell 
and then cultured for 48 hours. TRAIL blocking antibody (50 ng/ml) was added 24 
hours prior to infection with DENV. Intracellular DENV RNA levels were quantified 
by qRT-PCR. β-Actin mRNA was used as a control probe. The data presented are the 
means of five experiments for monocytes and two experiments each for B cells and 
HUVECs. Results for nonspecific antibody-treated monocytes are the means of three 
experiments (± SD). TRAIL blocking Ab increased DENV levels (p<0.02) as 
compared to non-specific Ab in monocytes. 
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At 48 h postinfection, monocytes incubated with anti-TRAIL showed a 0.7 ± 
0.3 (mean ± SD) log increase in DENV RNA levels relative to untreated, or to control 
antibody-treated cells (P < 0.02, unpaired Student's t test; n = 5). In duplicate  
experiments, an average 0.99 and 0.32 log increase in DENV RNA was observed in B 
cells and HUVECs, respectively (Fig. 10). Irrelevant antibody treatment did not affect 
DENV RNA levels in monocytes (0.008 ± 0.09 log increase in DENV RNA). Results 
from the antibody blocking experiments show that TRAIL protein has antiviral 
activity against DENV in vitro.  
 
(B) Addition of Exogenous recombinant TRAIL  
Monocytes and dendritic cells were treated with recombinant TRAIL to 
determine whether exogenous rTRAIL (Catalog# SE721-0100, Biomol and (Catalog# 
616374, Merck) was able to inhibit DENV replication. Inhibition of DENV RNA 
levels and antigen was used as a read-out of lower levels of DENV in monocytes and 
dendritic cells, respectively. 
Monocytes pretreated with 5 to 20 µg/ml of rTRAIL (Catalog# 616374, 
Merck) showed a 0.5 and 1 log decrease in DENV RNA copy number after 24 and 48 
hours, respectively (Fig. 11A). We also determined inhibition of DENV infection in 
DCs 48 hours postinfection. Since DCs are more efficiently infected by DENV than 
the other cells used, we were able to measure the percent DENV infected cells by 
flow cytometry. DCs treated with rTRAIL (20 µg/ml) showed a decrease of 67.5% ± 
22.9% (mean ± SD) in DENV (n=9) antigen-positive cells (data not shown). IFNγ 
(500 U/ml), which has previously been shown to inhibit DENV in DCs (78), inhibited  
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Time-point Experiment #        DENV Antigen Positive DCs
DENV DENV+rTRAIL DENV+IFNγ
1 21.2 12.7 1.2
2 20.7 0.6 0.5
3 1.6 1.0 0.8
4 1.9 0.7 0.4
48 hours
5 8.7 4.7 0.5
6 8.0 1.4 0.4
7 1.9 0.1 0.1
8 6.8 1.3 1.1
9 2.9 1.0 1.6  
 
 
Figure 11. rTRAIL treatment inhibits DENV infection. (A) Monocytes were infected 
with DENV at an MOI of 0.1 PFU/cell and then cultured for 24 and 48 hours. 
Monocytes were pretreated with rTRAIL 24 hours prior to infection with DENV. 
Intracellular DENV RNA levels were quantified by qRT-PCR. DENV RNA levels 
are obtained by applying the formula: DENV+rTRAIL / DENV for each dose of 
rTRAIL at each timepoint. β-actin mRNA was used as a control probe. Results are 
the means of two experiments. (B, C) DCs were pretreated with rTRAIL for 24 hours 
followed by infection with DENV2 or (C) DENV3 at an MOI of 0.1. At the 48-h time 
point the cells were stained intracellularly for DENV antigen (2H2 monoclonal 
antibody). (B) Data presented from one representative experiment of nine for DENV 
performed. (C) Data from all experiments are presented for cells treated with rTRAIL 
(20 µg/ml) DENV (n = 9) or IFNγ (500 U/ml) (n = 9). Data are presented as percent 
DENV antigen positive DCs following DENV infection or DENV infection and 
rTRAIL or IFNγ treatment. FITC, fluorescein isothiocyanate; APC, allophycocyanin. 
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DENV antigen-positive cells by 81.5% ± 20.3% (mean ± SD) (n=9) (data not shown). 
Percentage of DENV antigen positive DCs following infection and rTRAIL and IFNγ 
treatments are shown in Figure 11B and Figure 11C. 
Overall, the data from experiments using TRAIL inhibition by antibody and 
addition of exogenous rTRAIL demonstrate that TRAIL inhibits DENV infection in 
primary human cells, in vitro. 
 
TRAIL inhibits production of DENV progeny virus 
Previous experiments showed that TRAIL can lower DENV RNA levels and 
DENV antigen expression in multiple cell types (Figure 10 and Figure 11). Next, we 
performed plaque assay on the dendritic cell culture supernatants to measure the 
effect of rTRAIL on production of infectious DENV progeny.  
DENV infectious progeny was significantly reduced (P < 0.007, paired 
Student's t test; n = 5) in the supernatant of DENV-infected DCs treated with rTRAIL 
(Figure 12). The range of inhibition was from 0.9 to 2.8 logs. Hence, TRAIL can 
inhibit infection and replication of DENV in primary human cells in vitro. 
 
TRAIL antiviral function in DCs is independent of apoptosis 
A majority of previously published reports have found that TRAIL functions 
by inducing apoptosis of tumor cells and cell lines (26, 102, 133, 223, 238). However, 
most primary cells are resistant to TRAIL-mediated apoptosis (171, 184). TRAIL has 
also been shown to either inhibit viral infections or induce viral infection induced 
pathology during measles virus (219), cytomegalovirus (175) (205), reovirus (42) and  
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Figure 12. rTRAIL reduces levels of DENV progeny in DENV-infected DCs. DCs 
pretreated with rTRAIL for 24 hours were infected with DENV for 48 hours at an 
MOI of 0.1. At the end of the experiment culture supernatants were collected and 
stored at –70°C. DENV titers were determined by plaque assay on LLC-MK2 cell 
monolayers. Inhibition of DENV titers was observed in rTRAIL-treated DENV-
infected DC supernatants. Results for five independent experiments are shown. 
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(B) Active Caspase-3 
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Figure 13. Absence of apoptosis in rTRAIL-treated DENV-infected DCs. DCs were 
pretreated overnight with rTRAIL as described in Materials and Methods, followed 
by infection with DENV for 48 hours at an MOI of 1. Live/Dead Aqua and Caspase-3 
fluorescence was used to identify apoptotic DCs at 12 hours (A) and 24 hours (B). 
Live/Dead Aqua, Caspase-3 and PARP-1 fluorescence was determined at 48 hours 
(C) after rTRAIL treatment and DENV infection. Data from a representative 
experiment are shown for each time point. FITC, fluorescein isothiocyanate; APC, 
allophycocyanin. DCs treated with camptothecin B (2 mM/ml) for 4 hours were used 
as a positive control for caspase-3 stain at each time point (data not shown). 
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adenovirus (205) infection in an apoptosis-dependent manner. Hence, we investigated 
whether rTRAIL-mediated inhibition of DENV was dependent on apoptosis of 
DENV-infected primary cells. DENV-infected DCs pre-treated with or without 
rTRAIL were stained for DENV antigen and Live/Dead Aqua dye or early (caspase-
3) and late (PARP-1) markers of apoptosis at 12, 24 and 48 hours postinfection.  
The decrease in DENV infection of rTRAIL-treated DCs at the 12, 24 and 48 
hour timepoints postinfection did not correlate with an increase in staining with active 
caspase-3, Live Dead Aqua dye (Catalog#L34957, Invitrogen), or cleaved PARP-1 
proteins, which respectively detect early to late stages of apoptosis (Fig. 13 A, B, C). 
In some of the experiments, for Live/Dead Aqua and Active caspase-3 stain, fewer 
cells are seen in the flow cytometry plots due to unequal allocation of DCs to stain for 
controls and not as a result of fewer cells at the end of the experiment. I did count 
dendritic cells at the start and end of few experiments and found no decrease in DCs 
following rTRAIL or IFNγ treated DENV-infected DCs as compared to DENV-
infected DCs. Camphothecin-B treated DCs stained positive for apoptosis markers 
suggesting that the DCs used in the experiment were capable of undergoing 
apoptosis. These data suggest that TRAIL inhibits DENV in an apoptosis-
independent manner. The apoptosis-independent inhibition of DENV is novel since 
TRAIL mediated inhibition of other viruses or TRAIL mediated pathology by viruses 
like influenza, reoviruses, HIV, measles virus, CMV and EMCV is postulated to be 
apoptosis-dependent. 
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TRAIL anti-viral function requires pre-treatment for optimal DENV inhibition  
Kumar-Sinha et al. had shown that rTRAIL treatment induced expression of different 
genes depending on the time period of pre-treatment (108). Therefore, to understand 
the mechanism of action of rTRAIL-mediated inhibition of DENV we determined the 
time-point of pre-treatment required for rTRAIL to affect its antiviral function. DCs 
were treated for 24 hours, 12-15 hours, 30 min or 0 hour before infecting the cells 
with DENV for 48 hours.  
We found that 24 hour, 12-15 hour and 30 min pre-treatment with rTRAIL 
inhibited the percentage of DENV antigen-positive cells at the 48 hour timepoint after  
infection (Fig. 14).   
 
TRAIL mRNA induction is dependent on a functional IFNα signaling pathway 
IFNα/β can induce expression of TRAIL in many cell types (56, 88). Tyk2, 
STAT1, JAK1, and IFNαR 2c mutants (U1A, U3A, U4A, and U5A) derived from 
wild-type fibroblast cells (2fTGH) were used to determine whether the type-I IFN 
signaling pathway regulates TRAIL mRNA induction during DENV infection. 
TaqMan qRT-PCR was used to quantify TRAIL mRNA levels.  
Unlike the wild-type cells, none of the mutant cell lines showed up-regulation 
of TRAIL in response to DENV infection (Fig. 15). These data show that type I IFN 
signaling is necessary for TRAIL mRNA induction. 
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Figure 14. Effect of pre-treatment of DC with rTRAIL for various time periods prior 
to DENV infection. DCs were pre-treated with rTRAIL for 24 hours, 12-15 hours, 30 
min or 0 hours before infection with DENV. At 48 hour after infection, cells were 
stained for DENV antigen (DENV-FITC, 2H2 Ab). (A) Data from one representative 
experiment showing percent DENV antigen positive cells. (B) Data are presented as 
percent inhibition of DENV antigen at 48 hours postinfection in rTRAIL pre-treated 
cells as compared to DENV-infected cells.  Results for the two independent 
experiments performed are shown. 
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TRAIL anti-viral function requires signaling through the IFNα-receptor 
The type-I IFN signaling pathway is important for control of DENV infection 
in studies in mice and in vitro experiments (51, 52, 194). We found that DENV 
infection-mediated TRAIL mRNA induction was dependent on the type-I IFN 
signaling pathway. Hence, we tested whether antiviral activity of rTRAIL was also 
dependent on a functional type-I IFNR signaling pathway. When DENV-infected 
DCs were pre-treated with type-I IFN receptor blocking Ab (anti-IFNαR Ab) along 
with rTRAIL, most of the rTRAIL-mediated antiviral effect was inhibited (Fig. 16). 
In separate experiments, we confirmed that antiIFNαR Ab blocked the inhibition of 
DENV by exogenous IFNα (300U/ml) pre-treatment. These results suggest that  
rTRAIL-mediated inhibition of DENV was partly dependent on a functional type-I 
IFNR pathway. antiIFNαR Ab treatment did not completely block the antiviral 
activity of rTRAIL against DENV, which suggests that type-I IFN-independent 
mechanisms also contribute to the rTRAIL-mediated inhibition of DENV infection.  
 Moreover, data from the representative experiment in Figure 16 shows that 
antiIFNαR Ab treatment of either DENV-infected cells or DENV-infected cells 
treated with rTRAIL increased DENV antigen positive cells by 50% as compared to 
both DENV-infected cells and DENV-infected cells treated with rTRAIL. Hence, 
another possible explanation of the results from Figure 16 is that the decrease in 
DENV antigen following antiIFNαR Ab treatment of rTRAIL treated cells was due to 
inhibition of the antiviral effect of type-I IFN, but not rTRAIL, against DENV. This 
hypothesis suggests that rTRAIL inhibits DENV by a type-I IFN independent 
mechanism.
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Figure 15. TRAIL induction in response to DENV infection is type-I IFN dependent. 
2fTGH (wild type) and U1A, U3A, U4A, and U5A (type-I IFN mutant) fibroblast 
cells were infected with DENV at an MOI of 1 PFU/cell and then cultured for 48 h. 
TRAIL mRNA levels were quantified by qRT-PCR analysis. β-actin mRNA, a 
constitutively expressed protein, was used as a control probe. Results are 
representative of two independent experiments. 
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Figure 16. Type-I IFN receptor blocking Ab inhibits rTRAIL-mediated antiviral 
activity against DENV in DCs. DCs were pretreated with anti-IFNαR Ab (5ug/ml) 
for 30 hours before infection with DENV. Six hours post anti-IFNαR Ab treatment, 
rTRAIL (20ug/ml) was added to the cell culture. DCs were infected with DENV at an 
MOI of 0.1 for 48hours. Cells were stained intracellularly for DENV antigen (2H2 
monoclonal antibody). (A) Data from one representative experiment is shown. (B) 
Data are presented as percentage of DENV positive DCs from three independent 
experiments(n=3).  
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TRAIL suppresses the production of pro-inflammatory cytokines and 
chemokines in DENV-infected dendritic cells  
Activation and expansion of serotype cross-reactive memory T cells during 
secondary DENV infections alters the T cell phenotype to production of 
inflammatory rather than cytototoxic T cell proteins (16, 145). Elevated levels of Th1 
pro-inflammatory cytokines (IFNγ, TNFα, IL6, IL-1β, IL-2) and various chemokines 
(IL-8, MIP-1β, MCP1, RANTES) have been detected in dengue infected patients’ 
serum / plasma, and the expression of some of these mediators seems to be related to 
the severity of the disease (37, 63, 64, 96, 121, 176). Hence, treatment of DENV 
infection should involve regulation of the pro-inflammatory cytokine and chemokine 
response along with inhibition of DENV titers to prevent DENV infection mediated 
immunopathogenesis. 
A recent study by Secchiero et al. showed that TRAIL inhibits the TNFα- and 
IL1β-induced adhesion of leukocytes of HUVECs and HAECs (185). The inhibition 
of the leukocyte adhesion to HUVECs and HAECs was not due to interference of 
NFκB mediated up-regulation of ICAM1, VCAM-1 and E-Selectin-1.  However, the 
inhibitory effect of TRAIL was due to the down-modulation of the expression of 
TNFα-induced chemokines MCP-2 and IP-10 (185). Our laboratory found that levels 
of MCP-2 and IP-10 were significantly higher in sera from patients with dengue 
during the acute stage of the disease (I Bosch, unpublished data). In addition, TNFα, 
ITAC, IL-6, MIP-1β, IP-10, IL-8 and IL1β are among the pro-inflammatory 
chemokines and cytokines elevated during DENV infection in patients (61, 64, 80, 
81, 96, 121, 176, 222).  TRAIL was earlier found to be induced following DENV 
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infection in primary human cells, in vitro. Hence, we wanted to investigate whether 
rTRAIL might also function to downregulate the expression of MCP-2, IP-10 and 
maybe other pro-inflammatory cytokines and chemokines induced by DENV 
infection during acute phase of the disease, in vivo. To address this hypothesis, we 
studied the effect of rTRAIL pre-treatment on DENV-induced expression of pro-
inflammatory genes, MCP-2, IP-10, IL-6, TNFα, ITAC and IL-8. Several of these 
proteins have been implicated in the immune-mediated increase in vascular 
permeability observed in patients with DHF (81, 176, 222). To investigate whether 
the effect of rTRAIL treatment was specific to pro-inflammatory gene expression, we 
also included antiviral genes IFNα, MDA-5 and IRF7 in the list of genes being tested 
for the level of expression in rTRAIL treated DENV-infected cells. Inhibition of 
DENV RNA levels was used as a positive control for the effect of rTRAIL treatment.  
rTRAIL pre-treatment effectively suppressed the DENV infection-mediated 
increase in mRNA expression levels of the pro-inflammatory genes, MCP-2, MIP-1β, 
IP-10, IL-6 and TNFα (Fig. 17).  
As compared to DENV-infected DCs, rTRAIL treatment inhibited IP-10 
(90.5%), MCP-2 (84.6%), MIP-1β (67.4%), TNFα (61.3%), IL-6 (85.2%) and, to a 
lesser extent, IL-8 (29.2%) (Fig. 17). The two antiviral genes tested showed some 
suppression in expression: MDA-5 (53.3%) and little suppression of IRF-7 (34.4%) 
(Fig. 17). The suppression of cytokines and chemokines that can induce vascular 
permeability (TNFα), coagulation (IL-6) and recruit activated leukocytes (IP-10, 
MCP2 and MIP-1β), suggests a role for TRAIL in suppressing the pro-inflammatory 
response to DENV infection. 
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Figure 17: Percent mRNA levels in rTRAIL treated DENV-infected DCs compared 
to DENV-infected DCs. mRNA relative quantification using the 2-ΔΔCt method (131); 
β-actin was used as an endogenous control (Gene whose expression levels are fairly 
constant at any time inside the cell). Mean values ± standard error of mean are 
presented. N indicates the number of independent experiments. 
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Next, we determined if the decrease in expression of the pro-inflammatory 
cytokines and chemokines was also seen at the protein level.  Hence, we further 
analyzed the levels of MCP-2, IP-10, IL-6, ITAC and IFNα protein in cell culture 
supernatants from DENV-infected and rTRAIL pre-treated DENV-infected DCs at 
the 48 hours time point.  
All the proteins tested were detected at significantly lower levels in 
supernatants from rTRAIL pre-treated DENV-infected DCs as compared to 
supernatants from DENV-infected DCs, confirming the mRNA expression data (Fig. 
18). Thus, rTRAIL treatment inhibits both expression and secretion of pro-
inflammatory chemokines and cytokines in response to DENV infection in vitro. 
Taken together, these data suggest that TRAIL could function as a negative regulator 
of pro-inflammatory genes induced by DENV-infected DCs. 
TRAIL protein levels in Dengue patient serum 
TRAIL was induced at mRNA and protein level following DENV infection, in 
vitro. In addition, TRAIL exerted both, antiviral function against DENV and 
suppressed pro-inflammatory cytokines and chemokines induced by DENV infection 
in primary human cells, in vitro. Based on this in vitro data we hypothesize that 
TRAIL might have potential to treat DENV infection, in vivo. Hence, we wanted to 
determine and compare levels of TRAIL protein in DENV patient serum. We also 
determined the level of TRAIL in OFI patient serum to know how specific TRAIL 
expression was for DENV infection. 
TRAIL levels in serum from DENV-infected patients (N=19) were increased 
during the febrile days of the disease and dropped close to normal levels after 
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defervescence (Fig. 19). We found statistically significant differences in TRAIL 
serum levels between DENV-infected patients and OFI (N=4) during the febrile days 
of the disease (p<0.02).  
There were no significant differences between TRAIL levels in serum from 
OFI and healthy donors after the febrile phase of the disease. 
Interestingly, kinetics of TRAIL serum levels found in this study seems to co-
relate with DENV levels in DENV patients based on previously published clinical 
reports. The kinetics of TRAIL protein levels in dengue patient serum lends support 
to our previously published antiviral activity against DENV in human primary cells. 
 
Chapter Summary 
The results from Chapter IV identified TRAIL as a potential common linker 
of the type-I and type-II common response genes. Initial experiments performed in  
this section of the thesis demonstrate that TRAIL expression is induced in monocytes, 
B cells and DCs following DENV infection and this TRAIL protein expression is 
early (12 hour postinfection), transient atleast in dendritic cells. Experiments where 
either endogenous TRAIL protein was blocked using a TRAIL neutralizing Ab or 
exogenous rTRAIL was added to the cell culture showed that TRAIL has potent 
antiviral activity against DENV, atleast in vitro. We found that rTRAIL inhibited 
DENV in a novel apoptosis-independent manner which has not been demonstrated for 
TRAIL mediated inhibition of any other virus. Using wild type fibroblast cells 
(2fTGH) and type-I IFN pathway mutant cells derived from 2fTGH cells we 
investigated whether increased TRAIL mRNA expression was dependent on a  
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Figure 18. Effect of rTRAIL pre-treatment on MCP-2, IP-10, ITAC, IL-6 and IFNα 
levels in culture supernatants from DENV-infected DCs. DCs were incubated with or 
without rTRAIL (20 ug/ml) for 24 hours and then infected with DENV at M.O.I. of 
0.1 for 48 hours. Levels of (A) MCP-2, (B) IP-10, (C) IL-6, (D) ITAC, and (E) IFNα 
in supernatants from DENV-infected DC (white bars) and rTRAIL-pretreated DENV-
infected cells (black bars) at 48 hours post-infection were determined by commercial 
ELISA (N=3-7). Errors bars represent standard error of the mean for each treatment. 
Mann–Whitney analysis showed significant differences for MCP-2 (p<0.05); IP-10 
(p<0.02); ITAC (p<0.01); IFNα (p<0.02) when comparing DENV-infected versus 
rTRAIL pre-treated / DENV-infected DCs. (F) Percentage of DENV antigen-positive 
DC in DENV-infected (white bars) and DENV-infected + rTRAIL (black bars) 
cultures determined by flow cytometry. Paired t-test analysis showed a significant 
difference (p<0.03). 
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Figure 19. Serum TRAIL levels in DENV (black bars) and OFI (white bars) patients. 
TRAIL protein levels were determined during three phases of the disease: febrile, 
post-febrile and convalescence (Conv.) in both, OFI and DENV patient samples. 
Results are expressed as a mean ± standard error of mean. The mean TRAIL level in 
sera of healthy donors was 33.7 ± 8.8 (N=8) pg/ml. Mann–Whitney statistical 
analysis showed significant differences in TRAIL serum levels between OFI and 
dengue during febrile phase of the disease (p<0.02). Conv.: convalescence. 
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 functional type-I IFN signaling pathway. We found that a functional type-I IFN 
signaling pathway was required for DENV infection induced TRAIL expression. 
Adding IFNαR blocking Ab to the rTRAIL treated cells infected with DENV lead to 
an increase in DENV antigen levels. This data suggests that either most of the 
antiviral activity of rTRAIL is type-I IFN signaling pathway dependent or IFNαR 
blocking Ab blocked type-I IFN mediated antiviral activity against DENV without 
affecting the antiviral effect of rTRAIL against DENV. 
Pro-inflammatory cytokines (IL-6, TNFα) and chemokines (MCP-2, IP-10, 
MIP-1β, ITAC) elevated in response to DENV infection in DCs were suppressed both 
at mRNA and protein level following rTRAIL treatment. Elevated serum levels of 
TRAIL protein were also detected in DENV patients during febrile phase of the 
disease as compared to OFI patient and healthy donor serum samples. 
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Chapter V 
 
Identification of sST2 and IDO as biomarkers for DENV infection and role of 
IDO activity in IFNγ - mediated inhibition of DENV infection 
Potential DENV-specific response genes were confirmed in DENV-infected 
HUVECs, in vitro and in dengue patient and OFI patient PBMCs isolated during the 
acute phase of the disease. The OFI and dengue patient analysis confirmed that ST2 
and IDO genes were induced to a greater extent in DENV patient PBMCs as 
compared to OFI patient PBMCs.  
We focused the experiments in this section of the thesis on confirming 
specificity (biomarker) of their upregulation in DENV patient serum and to 
understand their function in relation to DENV infection. 
 
sST2 and ST2L mRNA levels in DENV-infected HUVECs 
One of the genes found to be upregulated in the “common” gene expression response 
to DENV infection was ST2. However, multiple forms of ST2 are expressed via 
alternative mRNA splicing, and the Affymetrix GeneChip probe hybridized to the 
mRNA of both soluble (sST2) and cell surface bound (ST2L) isoforms. Hence, we 
hypothesized that both or either one of these two isoforms could be responsible for 
detection of higher ST2 mRNA in samples tested. To address this hypothesis, we 
analyzed the expression of sST2 and ST2L mRNAs in DENV-infected HUVECs by 
semi-quantitative RT-PCR. We designed forward and reverse primers specific either 
to the sST2 or the ST2L isoform of the gene.  
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We found that soluble ST2 mRNA transcripts were much more abundant in 
DENV-infected HUVECs as compared to uninfected HUVECs at the 48hour 
timepoint of infection (Fig. 20). ST2L mRNA was also slightly differentially 
expressed. However, no ST2L protein was detected on the surface of DENV-infected 
HUVECs at the 48 hour timepoint by flow cytometry (data not shown). The result 
that sST2 isoform expression is induced in DENV-infected HUVECs suggests but 
does not confirm that the upregulated ST2 mRNA detected in PBMCs from DENV-
infected patients was the sST2 isoform. 
 
sST2 protein levels in DENV patient serum 
The data in HUVECs showed that sST2 isoform is upregulated in response to 
DENV infection. Cytokines such as IL-1β, TNFα, IL-6, which are elevated in DENV 
patient serum are known to induce sST2 expression (123, 164, 207). Moreover, 
TNFα and IL-6 are significantly higher in DENV-infected patients with symptoms of 
DHF/DSS (64, 81).  
To determine if production of sST2 was induced specifically in DENV 
patients, we tested dengue patient serum for levels of sST2 protein during the acute 
stage of the disease.  
We found a statistically significant increase in serum sST2 levels in DENV 
patients during the acute stage of the disease (Fig. 21A). The serum levels of sST2 
were similar to levels in OFI patient serum by the convalescent day. The highest 
levels of  
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Figure 20. Soluble ST2 is transcriptionally induced in DENV-infected HUVECs, in 
vitro. HUVECs were infected with DENV at MOI of 1. After 48 hours of infection 
RNA was extracted from cells and sST2 and ribosomal protein L35a mRNAs were 
amplified using semi-quantitative RT-PCR. The first 2 lanes for both genes represent 
control medium (C6/36, insect cell supernatant) and the 3rd and 4th lane represent two 
DENV-infected HUVEC sample. Results from two independent experiments are 
shown. 
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Figure 21. Soluble ST2 (sST2) levels in serum from patients during the course of the 
disease were quantified by ELISA. Fever day 0 is the day of defervescence. Fever 
days -2 and -1 are febrile days. Fever days +1 and +2 are post-febrile days; conv is 
the convalescent day. Upper panel: Other Febrile Illness (OFI) (N=11) and dengue 
patients (N=24); significant differences were found in sST2 levels between OFI and 
dengue patients on fever days -1 (p<0.01) and 0 (p<0.01). Lower panel: dengue 
patients classified as Primary (N=10) or Secondary (N=13) infections; significant 
differences were found in sST2 levels between primary and secondary infections on 
fever days -1 (p<0.04) and 0 (p<0.03). sST2 levels in the serum from normal donors: 
15.9±4.4 pg/ml (N=14). Non-parametric statistical analysis using Mann-Whitney U 
test was utilized. Bars represent mean values, with error bars showing SD. 
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sST2 were detected on fever days –1 and 0, suggesting that sST2 may be a marker for 
DENV infection in patients during the late phase of the infection. Among dengue 
patients, higher sST2 levels were detected during secondary as compared to primary 
dengue infections (Fig. 21B) suggesting that sST2 might be a potential biomarker for 
secondary dengue infections.  
 
IDO mRNA levels in uninfected, DENV-infected and IFNγ treated + DENV-
infected DCs 
IFNγ is known to induce IDO mRNA gene expression. We confirmed whether 
the induction of IDO mRNA was due to DENV infection or IFNγ or both using the 
DC model for DENV infection. DENV infection alone induced IDO expression in 
DCs (Table 6). Moreover, IFNγ pre-treatment increased the expression of IDO gene 
after DENV infection (Table 6).  
All the DCs were infected with DENV at an MOI of 0.1. Infection was 
stopped at the 48 hour timepoint and RNA was extracted from cells. IDO mRNA 
levels were quantified using qRT-PCR. Data from three experiments are presented. 
Error bars represent standard error of the mean. 
 
Increased IDO activity in dengue patient serum 
IFNγ has been shown to induce IDO activity to mediate part of its antiviral 
function (4, 160). IDO mediated tryptophan depletion also plays a role in the 
immune-modulatory function in APC - T cell interactions (138, 150). Furthermore, 
higher IFNγ levels have been documented in dengue patients by multiple studies. We  
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 Experiment No. IDO mRNA Fold Induction 
 DC+DV DV+DV+IFNγ 
1 2 14 
2 14 75 
3 306 2851 
 
                                                                          
Table 6. IFNγ treatment substantially increases the DENV infection mediated 
expression of IDO. Monocyte-derived DCs were generated as mentioned in Chapter 
II. DCs were either pre-treated or not with IFNγ (500U/ml) for 12-16 hours. Results 
for three independent experiments are shown. 
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hypothesized that the higher systemic IFNγ levels would increase IDO activity in 
DENV patients. Hence, we determined IDO activity in patient serum. IDO enzyme 
catalyzes the metabolism of tryptophan to kynurenine, the rate-limiting step in the 
kynurenine pathway of tryptophan degradation. Determining the tryptophan quotient 
[(kynurenine/tryptophan)*100], which is an indirect method to demonstrate IDO 
enzyme activity has been extensively used to identify increased IDO activity.  
Increased IDO activity was detected in dengue patient serum as compared to 
OFI patient serum (Fig. 22). The levels of tryptophan were significantly lower in 
dengue patient serum during the acute, post-febrile and convalescent stages of the 
disease which might be a result of higher IDO activity and lower intake of nutrition 
due to weakness, vomiting and nausea. Kynurenine levels were significantly 
increased during the febrile stage of the disease, but decreased during the post-febrile 
stage and were similar to kynurenine levels in OFI patients by the convalescent day. 
The IDO activity was significantly higher in dengue patient serum during all phases 
tested. However, the significance and level of IDO activity was much higher during 
the acute and post febrile phase of the disease. The results indirectly show that IDO 
enzyme activity was strongly induced in dengue patients.  
 
IFNγ-mediated antiviral function is partly dependent on IDO activity  
The function of IDO is to metabolize tryptophan, an essential amino acid, to 
kynurenine. IFNγ treatment has been previously reported to induce IDO gene 
expression and to utilize IDO activity as a part of its antiviral function (4, 160, 172).  
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Figure 22.Tryptophan and kynurenine levels in serum from OFI (N=5) and dengue 
patients (N=6) during acute, post-febrile and convalescent days were measured using 
mass spectrometry. Bars represent mean values (-/+ SEM). Values for healthy donors 
(N=5) are: tryptophan: 13.24 (±0.85) ug/ml and kynurenine: 0.66 (±0.09) ug/ml. 
Unpaired t-test analysis to compare OFI vs. dengue was performed. All the DENV 
patients in this study were clinically defined as DF by WHO criteria. IDO activity = 
(kynurenine / tryptphan)*100. 
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We hypothesized that IFNγ utilizes IDO enzyme activity as part of its antiviral 
activity against DENV infection. Hence, we tested the role of IDO activity in the 
IFNγ-mediated inhibition of DENV using the DC model. Treatment with 1-methyl 
tryptophan (1-MT), a synthetic analogue of tryptophan was used to block IDO 
activity (172, 206).  
IFNγ inhibited DENV infection as shown by a reduction in antigen-positive 
cells, consistent with previously published results. 1-MT treatment restored an 
average 66% of DENV RNA levels inhibited by IFNγ treatment (Fig. 23). This data 
indicate that IFNγ activates IDO activity as a part of its antiviral function.   
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DC+DENV DC+DENV + IFNγ DC+DENV+IFNγ + 1-MT
Experiment # 1 1 471.9 103.9
Experiment # 2 1 58.4 9.8
Experiment # 3 1 3.8 1.2
Experiment # 4 1 108 30
Fold Decrease in DENV RNA Levels
 
 
 
 
 
Figure 23. Inhibition of IDO activity reduces the IFNγ-mediated antiviral function 
against DENV. DCs were infected with DENV with or without pre-treatment with 
IFNγ (500U/ml) and 1-MT (1mM) for 12-16 hours before infection. All the DCs were 
infected with DENV at an MOI of 0.1 for 48 hours. Intracellular DENV RNA levels 
were quantified by qRT-PCR. β-actin mRNA was used as a control probe. Data are 
presented as inhibition of DENV RNA levels. Results for four independent 
experiments are shown.   
 
 
 
 
  105
Discussion 
 
 
 
Identification of antiviral and biomarker genes against dengue virus 
 
The goal of the present project was to identify cellular responses to DENV 
infection by means of studying gene expression and identify (i) potential protein 
biomarkers of DENV infection and (ii) potential antiviral proteins. Specifically, we 
hypothesized that there is a set of cellular genes, which is necessary to clear DENV in 
susceptible human cells. We initially set out to identify gene expression changes 
induced in primary human cells by DENV infection using global gene expression 
analysis. The analysis identified a common gene expression profile of 23 
differentially regulated genes in DENV-infected peripheral blood mononuclear cell 
subsets (B cells and monocytes) and HUVECs. TRAIL, one of the common response 
genes, was identified as a potential common linker between the IFNα and IFNγ 
signaling pathway inducible common response genes, was selected for further study.  
Endothelial cells play a central role in the clinical presentation of the 
symptoms of DHF/DSS, such as increased vascular permeability, hypovolemic shock, 
bleeding, circulatory failure and haemoconcentration. In vitro and findings in mice 
have shown that endothelial cells are targets for DENV infection (7, 36, 225). In vivo, 
lung vascular endothelial cells and sinusoidal endothelial cells have stained positive 
for DENV antigen (92). With the goal of identifying biomarkers for DENV infection, 
we initially focused on understanding the effect of direct DENV infection on 
HUVECs. Gene expression analysis in DENV-infected HUVECs was compared to 
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gene expression analysis in cells infected with other RNA viruses (WNV, YFV, 
Hantaan and SNV). Global gene expression analysis identified a set of 30 genes 
potentially differentially regulated in DENV-infected HUVECs as compared to 
HUVECs infected with the other RNA viruses mentioned above. Among the genes 
that were confirmed for differential expression, IDO and ST2 were found to be 
specifically regulated in PBMCs from DENV-infected patients as compared to OFI 
patient PBMCs and were selected for further study.  
 
TRAIL Gene: 
(i) Expression  
(ii) Antiviral function  
(iii) Pro-inflammatory gene inhibition 
 
(i) TRAIL Expression  
Gene expression analysis in DENV-infected HUVECs, B cells and monocytes 
identified a set of 23 common response genes. Among the 23 common response 
genes, 11 genes, other than TRAIL were confirmed for their differential expression 
due to the unavailability of TaqMan qRT-PCR primers and probes for the other 11 
common response genes. (Table 3). The induction of TRAIL mRNA expression by 
DENV infection was confirmed in multiple DENV-permissive primary human cells. 
Upregulation of TRAIL expression was also confirmed at the protein level in DENV-
infected cells. We were unable to detect secreted TRAIL protein in the supernatant 
from DENV-infected primary monocytes and dendritic cells, but TRAIL protein 
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levels were highly induced in lysates of DENV-infected monocyte. We used DC to 
determine the pattern of expression of TRAIL protein following DENV infection; 
DENV-infected dendritic cells were double-stained for DENV antigen and TRAIL 
protein by cell surface and intracellular cytokine staining (ICS) assay. However, 
using flow cytometry we were unable to detect TRAIL on the surface of monocytes or 
DCs following DENV infection. One possible explanation for these results is rapid 
internalization of TRAIL protein, or due to its storage and release inside cytoplasmic 
vesicles (147). While uninfected DCs cultures did not express any detectable TRAIL 
protein, TRAIL expression was detected in infected cultures early but transient 
following DENV infection. The upregulation of TRAIL protein expression occurred 
early (at 12 hours post infection) and was transient, with reduced staining at 24 and 
48 hours post-infection. In summary, based on our data, TRAIL mRNA and protein 
are upregulated early and transiently after DENV infection in DENV-infected cells. 
One possible explanation for the lack of TRAIL expression in infected cells, 
compared to bystander cells, is the direct effect that the virus may have on signaling 
in the infected cell. IFNα is a known strong inducer of TRAIL transcription, while 
DENV has been shown to inhibit IFNα signaling in infected cells (95, 152, 153). 
Thus, TRAIL expression may not have been detected in DENV-infected DCs due to 
inhibition of IFNα signaling.  
We used wild-type (2fTGH) and type I IFN mutant (U1A (TYK2), U3A 
(STAT1), U4A (JAK1), and U5A(IFNR-2.2) human fibroblast cell lines (132, 137, 
169) to determine whether the increased TRAIL expression induced by DENV 
infection was IFNα-dependent. Increased TRAIL mRNA expression was detected 
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only in wild type 2fTGH cells, showing that a functional IFNα signaling pathway 
was required for the induction of TRAIL expression following DENV infection. This 
finding supports the hypothesis that blocking of IFN type I receptor signaling by 
DENV blocked the induction of TRAIL gene expression. 
Recently, Matsuda et al. reported that TRAIL protein secreted by HepG2 cells 
after DENV infection was partly responsible for apoptosis of uninfected HepG2 cells 
(136). Global gene expression analysis in DENV-infected HepG2 cells and primary 
cells (DCs, monocytes, B cells, and HUVECs) performed in our laboratory has shown 
a distinct set of differentially regulated genes in HepG2 versus primary human cells 
(Fig. 1B). Unlike primary cells, TRAIL mRNA levels were not up-regulated in 
DENV-infected HepG2 cells. We believe that DENV infection of primary cells may 
better reflect a physiological response. In the previous study of Matsuda et al., 80% of 
DENV-infected HepG2 cells stained positive for cell death (136), raising the 
possibility that the TRAIL protein detected in the supernatant of DENV-infected cells 
was not secreted but resulted from cell death. In contrast, DCs infected with DENV 
showed minimal staining with the apoptosis detection dye (Live/Dead Aqua) or other 
markers of apoptotic cells (PARP-1 and caspase-3).  
One possible explanation of the IFNαR blocking experiments is that majority 
of the in vitro antiviral activity of TRAIL against DENV is IFNαR-dependent. In 
addition, DENV infection-induced TRAIL gene expression was dependent on a 
functional IFNα signaling pathway, in vitro. Hence, we wanted to know whether the 
kinetics of TRAIL expression followed the known pattern of IFNα expression levels 
in DENV patients (124). TRAIL protein expression was determined in febrile, 
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postfebrile and convalescence samples of serum from DF patients. The kinetics of 
TRAIL serum levels correlated with IFNα and DENV levels reported in previous 
studies (124); TRAIL protein levels peaked during the febrile phase of the disease 
and returned to baseline levels by the post-febrile phase of the disease.  
 
(ii) Anti-viral function of TRAIL 
In vitro and in vivo studies have demonstrated tumoricidal activity of TRAIL 
without significant toxicity toward normal cells or tissues (171, 184). TRAIL has 
been shown to mediate antiviral functions in vivo in mouse models of influenza and 
encephalomyocarditis virus infection (89). Influenza viral clearance was prolonged in 
mice injected with anti-TRAIL antibody. TRAIL expressed by NK cells was crucial to 
limit encephalomyocarditis virus replication in vivo (184).  
To determine the effect of TRAIL on DENV infection, we treated monocytes, 
B cells and HUVECs with anti-TRAIL Ab and monocytes and DCs with rTRAIL 
prior to infection with DENV. Multiple assays demonstrated that TRAIL is a potent 
antiviral molecule against DENV. Increase in DENV RNA levels following treatment 
with anti-TRAIL Ab indicates that TRAIL has antiviral activity against DENV and 
this activity is non-redundant. The reduction in DENV RNA levels suggests that 
TRAIL inhibits viral RNA production, which can affect protein synthesis. The lower 
detection of DENV antigen and reduction in plaque forming units per milliliter 
represents decrease in DENV infection and infectious viral progeny production, 
respectively. rTRAIL was procured from five different commercial sources- Merck 
(Catalog# 616374 & Catalog# 616375), UB Biological (Catalog# T8180), Alexis 
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(Catalog# 201-073-C020) and Biomol- and tested for antiviral activity against 
DENV. Of the five rTRAILs tested, rTRAIL obtained from Merck (Cat# 616375, 
discontinued) and Biomol (Catalog# SE-721) were functionally active in our study. 
The ability to induce apoptosis in cell lines like U937 cells or Jurkat cells is the only 
biological activity assay performed for all the commercially available recombinant 
TRAIL proteins including those tested in this study. rTRAIL treatment did not induce 
apoptosis of DENV-infected or bystander cells in this study. Recent studies have 
shown that rTRAIL also triggers apoptosis-independent functions in cells. We believe 
that the five commercially available rTRAILs might each signal differentially 
downstream after binding to the TRAIL-Rs, two of which (Biomol and Merck) 
induce genes involved in the antiviral activity of rTRAIL against DENV. In addition, 
the rTRAIL from Biomol and Merck have been used extensively to study TRAIL 
function (126, 142, 167). 
The concentration of Biomol rTRAIL (5 to 20 µg/ml) that was able to inhibit 
DENV replication in this study was similar to the concentration used in studies 
demonstrating TRAIL-induced apoptosis of tumor cells (2, 26). In the literature, 
TRAIL anti-cancer function has been associated with its ability to induce apoptosis 
(2, 3, 25, 26). To determine whether TRAIL inhibited DENV by an apoptosis-
dependent or -independent mechanism, we stained DENV-infected DCs pre-treated 
with TRAIL for Live/Dead Aqua, active Caspase-3 and cleaved PARP-1 protein. 
Live/Dead Aqua dye can permeate only into cells with compromised membranes 
(dead or dying cells). The dye can discriminate between live and dead cells by 
irreversibly binds to free amines, which are much more abundant inside rather than on 
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the cell surface. The extrinsic and intrinsic pathways of cell death converge at the 
activation of an effector enzyme, caspase-3. Caspase-3 is an early detection marker 
for cell death. PARP-1 mediates Poly(ADP-ribosyl)ation and PARP-1 activity 
represents an important pathway in the restoration of cellular integrity (86, 90). 
PARP-1 protein is cleaved by caspase-3 into two smaller fragments and detection of 
these fragments of PARP-1 protein is considered a sensor for early DNA damage 
(122). The presence of cleaved PARP-1 is widely used as an diagnostic marker of 
apoptosis in many cell types (63, 101). These studies showed neither increased DC 
apoptosis in DENV-infected DC cultures nor apoptosis of DENV antigen-positive 
cells. Thus, we conclude that exogenous recombinant TRAIL inhibited DENV-
infection in DCs by a novel apoptosis-independent mechanism. We hypothesized that 
TRAIL might be inhibiting DENV replication by acting as an antiviral agent and not 
by inducing apoptosis.  
TRAIL treatment has previously been shown to induce a different cohort of 
IFNα/β inducible genes, including transcriptional induction of IFNβ mRNA, at 
various timepoints following recombinant TRAIL treatment (108) suggesting a cross-
talk with the IFNα/β signaling pathway. If this finding was true for the effect of 
rTRAIL treatment on DENV infection, time-point of rTRAIL pre-treatment might 
also affect the antiviral activity of rTRAIL against DENV. Hence, we performed a 
time course of rTRAIL pre-treatment to determine whether rTRAIL antiviral activity 
against DENV was dependent on the timepoint of pre-treatment. The data indicate 
that 24hour pre-treatment with rTRAIL produced the maximal and reproducible 
inhibition of DENV. Our earlier experiment on antigen staining of DENV-infected 
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DCs had shown that only bystander cells expressed TRAIL protein following DENV 
infection. Hence, one possible explanation for the requirement of 24 hour pre-
treatment to inhibit maximal level of DENV could be that bystander cells require 
between 12-15 to 24 hours to express and secrete known antiviral cellular proteins 
which act upon DENV-infected cells. A previous study showed that at least 16 hour 
pre-treatment of cancer cells with rTRAIL was required to induce IFNβ transcription 
(108). Since we required 24 hours’ pre-treatment to observe maximal inhibition of 
DENV replication, it is possible that the antiviral activity of rTRAIL against DENV 
involves IFNα/β activity.   
IFNs enhance expression of TRAIL, while, on the other hand, TRAIL 
treatment can enhance expression of IFN-inducible genes like IFITM1, IFIT1, 
STAT1, LGal3BP, and PRKR as well as IFNβ itself (108). The molecular cross-talk 
and functional synergy observed between the TRAIL and IFN signaling pathways is 
not limited to the genes involved in apoptosis and may have implications for the 
physiologic role and mechanism of action of TRAIL protein. Data presented 
previously in this thesis has shown that DENV infection-induced TRAIL mRNA 
expression is dependent on a functional IFNα signaling pathway. To understand if the 
IFNα signaling pathway played a role in the antiviral activity of TRAIL, we pre-
treated DENV-infected cells with rTRAIL in the presence of IFNαR-blocking 
antibody. We observed an increase in DENN antigen following treatment with 
IFNαR-blocking Ab. One possible explanation for this finding is that part of the 
exogenous rTRAIL-mediated antiviral activity against DENV is dependent on 
IFNαR. This hypothesis supports the model that rTRAIL induces IFNα/β as a part of 
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its antiviral response against DENV. Based on the in vitro and in vivo data we 
speculate that TRAIL is involved in limiting DENV spread in vivo. 
 
(iii) Suppression of pro-inflammatory cytokine production by TRAIL 
Many studies have implicated the involvement of T cells in the pathogenesis 
of DHF/DSS (112, 145, 168). Cross-reactive T cell activation, proliferation and 
release of pro-inflammatory cytokines and chemokines that can directly affect the 
endothelial cells inducing plasma leakage is a widely-proposed model for DHF/DSS 
following DENV-infection (145, 146). Higher circulating levels of sCD4, sCD8, 
IFNγ, IL-2, TNFα, sTNFR, IL8, IL6, MIF and MCP1 have been detected in sera of 
patients with dengue (112). Also, DHF has been associated with higher serum levels 
of pro-inflammatory cytokines and chemokines like IL-2, TNFα, IL6, IL8, MCP1 
than DF (37, 63, 64, 96, 121, 176).  
Dendritic cells regulate initiation and activation of both the innate and 
adaptive immune responses. In addition, DCs are the principal antigen-presenting 
cells that regulate activation of NK cells and naïve and memory T cells (203). In vivo, 
DCs are important targets for DENV infection (230). Palmer et al. (166) and Libraty 
et al. (125) have further demonstrated that phenotypic changes occur in both 
uninfected bystander DCs and DENV-infected DCs in the same cell culture, 
suggesting that DENV alters DC activation and maturation. Hence, DCs are a good in 
vitro primary human cell model, which can be used to study effects of rTRAIL 
treatment on DENV infection-induced changes in cellular gene expression.  
Secchiero et al. (185) has recently shown that recombinant TRAIL completely 
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abrogated the TNFα-mediated increase in leukocyte adhesion to HUVECs by 
selectively downregulating the expression of IP-10 and MCP-2. This TRAIL 
treatment mediated modulation of leukocyte/endothelial cell adhesion did not 
interfere with the TNFα and IL-1β induced expression of VCAM-1, ICAM-1, E-
selectin and NFκB genes. Therefore, we determined whether TRAIL was able to 
suppress expression of MCP-2, IP-10, IL-6, TNFα, MIP-1β and IL-8, pro-
inflammatory chemokines and cytokines induced in response to DENV infection in 
DCs. We found that TRAIL significantly suppressed expression of MCP-2, IP-10, IL-
6, TNFα and MIP-1β mRNA levels induced as a result of DENV infection in DCs. 
We also demonstrated the suppression by rTRAIL of MCP-2, IP-10, ITAC, and IL-6 
protein secretion from DENV-infected DCs. Taken together, these data indicate that 
TRAIL can inhibit DENV replication and expression of pro-inflammatory genes. 
Some of the genes suppressed by rTRAIL treatment (IP-10, ITAC, MIP-1β TNFα 
and IL-6) have also been detected at higher levels in serum of dengue patients; of 
particular interest, TNFα and IL-6 serum levels correlate with the severity of dengue 
disease. 
One theoretical approach to treating DENV immunopathology is to find a 
molecule with the capacity to both inhibit viral replication and regulate pro-
inflammatory cytokine production. In vivo studies still need to be performed to 
establish the antiviral and anti-inflammatory functions of rTRAIL; however, we 
believe that the in vitro data suggest that TRAIL might be a therapy with dual 
beneficial function. 
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ST2 Gene:  
(i) Expression 
(ii)  Biomarker for DENV infection  
(iii) Biomarker for Primary versus Secondary DENV 
 
(i) ST2 Expression 
Alternative splicing of the ST2 gene generates three mRNAs, corresponding 
to a longer membrane-anchored form (ST2L), a shorter released form (sST2) and a 
membrane bound variant form (ST2V) (21, 215, 235). We detected increased ST2 
mRNA in DENV-infected cells, in vitro and dengue patient PBMCs, by quantitative 
RT-PCR. However, the TaqMan primer and probe used for this assay was not specific 
to any of the three isoforms of ST2 gene. To identify if the specific isoforms, sST2 or 
ST2L, were upregulated following DENV infection, we performed semi-quantitative 
RT-PCR analysis using primers specific for these two isoforms in DENV-infected 
HUVECs. The sST2 isoform of the ST2 gene was found to be more abundant and 
also clearly upregulated in DENV-infected HUVECs. The ST2L isoform was weakly 
expressed in uninfected HUVECs and slightly induced at the mRNA level in DENV-
infected HUVECs. However, no cell surface expression of ST2L was detected on 
HUVECs following DENV infection. We did not analyze ST2V mRNA and cell 
surface levels in HUVECs. In summary, the sST2 isoform of the ST2 gene was 
upregulated in DENV-infected HUVECs in vitro. These data do not conclusively 
prove that only the mRNA for sST2 isoform was upregulated in DENV patient 
PBMCs. Evidence of increased sST2 levels in sera of dengue patients further suggests 
  116
that the increased expression of ST2 gene mRNA identified in DENV patient PBMCs 
of dengue patients was of the sST2 isoform. However, further studies will be needed 
to determine ST2L and ST2V expression levels on the surface of PBMCs isolated 
from dengue patients during the acute phase of the disease. 
 
(ii) Biomarker for DENV infection 
sST2 has previously been proposed as a biomarker for heart failure (227). To 
determine the specificity of the increase in sST2 protein levels in patients with 
dengue, we compared sST2 levels in dengue patient serum to levels in serum of 
patients with other febrile illnesses (OFI). We found higher levels of sST2 protein in 
serum from DENV-infected patients as compared to serum from OFI patients. Serum 
levels of sST2 protein were elevated at the end of the febrile stage of the disease, 
reaching peak levels between fever day -1 and fever day 0 followed by decrease to 
normal levels by convalescence day. These data from a small number of dengue 
patients indicate that serum sST2 levels are a possible marker for DENV infection.  
 
(iii) Biomarker for Primary versus Secondary DENV 
Most of the patients in the clinical study were diagnosed as having DF, by 
serology.  Since DF patients composed the majority of our cohort, we analyzed the 
data on sST2 levels according to antibody titers, which allowed us to classify cases as 
primary or secondary DENV infections. Higher levels of sST2 protein were found in 
patients with secondary infections than in those with primary infections. Currently HI 
titers are used to differentiate between primary and secondary DENV infections (41). 
  117
Hence, serum levels sST2 is a possible marker for DENV infection and a promising 
candidate as a biomarker for secondary dengue infections. However, further tests 
need to be performed to determine the specificity and sensitivity of serum sST2 
detection test. Overall, a larger clinical study needs to be performed to confirm that 
sST2 is a marker for (i) DENV infection and (ii) secondary DENV infection. We also 
do not know which cells produce sST2 protein in vivo during DENV infections. 
Reports have suggested that sST2 protein regulates both the pro-inflammatory 
response as well as the Th2 immune response. Soluble ST2 reduced IL-33 induced 
production of IL-4, IL-5 and IL-13 in splenocytes (75). In addition, sST2 treatment of 
bone marrow-derived and alveolar macrophages can inhibit LPS induced pro-
inflammatory cytokines IL6, IL-12 and TNFα (164, 207). Soluble ST2 treatment was 
able to decrease TNFα levels elevated during ischemia reperfusion injury 
(characterized by local and systemic inflammation) (59). sST2 could act as a 
regulator of inflammation through a mechanism that involves the inhibition of Toll-
like receptor 4 signaling by sequestration of MyD88 and Mal adapter proteins (27)  or 
inhibition of NFκB activation by decreasing IκB degradation (209). Also, in vivo 
experiments have shown that sST2 protein was able to attenuate the production of 
pro-inflammatory cytokines IL-1β, TNFα, IL-6, and IL-12 in the murine collagen-
induced arthritis model (123). 
During secondary DENV infections, serotype-cross-reactive memory T cells 
from a previous infection prevail over the naïve T cells specific for the infecting 
serotype (55, 146). The activation of cross-reactive T cells may lead to suboptimal 
clearance of the virus and an excessive production of soluble mediators mimicking 
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“original antigenic sin” (145). High levels of pro-inflammatory cytokines like TNFα 
and IL-6 that have been found in dengue patients (8, 80, 81) can induce sST2 
expression (109, 208). In addition, DENV-infected monocytes and PBMC 
supernatant can induce vascular permeability (33, 50). The Fagundes et al. study also 
demonstrated that high dose of sST2 inhibited vascular permeability and hemorrhage 
(clinical symptoms also associated with DHF/DSS) in ischemia reperfusion injury 
induced intestine and lungs compared to control IgG treatment (59). Hence, we 
propose that elevated sST2 levels found in dengue patients could be an indication of 
immune hyperactivation as well as a mechanism to down-regulate the pro-
inflammatory cytokine response and maybe downregulate vascular permeability and 
hemorrhage associated with severe DENV infections.  
Overall, the findings in this study show a transient elevation of sST2 protein 
levels in serum of DENV-infected patients around the time of defervescence, as 
compared to sST2 protein levels in OFI patients. Results show that in our patients, 
levels of sST2 protein in serum were higher in patients with secondary infections. 
Severe clinical manifestations (DHF/DSS) correlate with secondary infections. 
Hence, understanding the molecular mechanism(s) involved in the regulation and 
biological effects of sST2 protein in DENV infections deserves further investigation 
including exposure of DENV-infected endothelial cells to pro-inflammatory 
cytokines or supernatant from DENV-infected monocytes and PBMCs in the presence 
of sST2 to determine the effect of sST2 protein on vascular permeability. 
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IDO Gene:  
(i) Expression 
(ii) Biomarker for DENV infection  
(iii) Antiviral function 
 
(i) IDO Expression 
IDO was another gene whose mRNA expression levels were higher in PBMCs 
from patients with dengue as compared to patients with OFI. Previous studies have 
shown that increased IDO activity plays a role in IFNγ-mediated inhibition of viruses 
(160). Heseler et al. (77). In addition, IFNγ is a potent inducer of IDO expression 
(180). We were interested in studying the function of IDO in IFNγ-mediated 
inhibition of DENV infection (or replication) in DCs. We found increased expression 
of IDO mRNA in DENV-infected DCs. The increase in IDO mRNA expression 
associated with DENV infection was further enhanced by IFNγ treatment. Thus, the 
data on IDO gene expression presented in this thesis indicate that both DENV 
infection and IFNγ can induce IDO gene expression in DENV-infected DCs. 
 
(ii) Biomarker for DENV infection 
Traditionally recognized for its role in pregnancy, transplantation, 
autoimmunity and neoplasia, the immunoregulatory enzyme IDO has been found to 
have potential in the control of virus infection and inflammation (67, 76, 138). IDO-
dependent tryptophan depletion has been reported as an antiviral mechanism used by 
IFNγ to regulate viral progeny (160). Increased IDO activity might also have a 
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beneficial role to regulate inflammation and protect peripheral cells like endothelial 
cells and hepatocytes from effector T cell-mediated cytotoxicity. IDO expressed in 
antigen-presenting cells was essential to protect allogenic liver graft from T cell 
attack, suggesting a role of IDO as a immunosuppressive molecule (127). Another 
study by Thebault P et al. demonstrated the essential role of IFNγ from regulatory 
CD4+CD25+ T cells to induce IDO expression in graft endothelial cells to induce 
tolerance to MHC mismatched rat cardiac allograft (212).  
IDO is ubiquitously distributed in mammalian tissues and cells (105). It 
catalyzes the initial and rate-limiting step in the catabolism of L-tryptophan along the 
kynurenine pathway (210). Determination of tryptophan and kynureneine levels is an 
indirect method of determining IDO enzyme activity (150). This indirect method was 
used to measure levels of IDO activity in sera from patients with dengue or OFI as 
well as healthy donor serum samples. We detected higher serum IDO activity in 
DENV-infected patients as compared to patients with OFI and healthy donors. Hence, 
we present evidence that increased serum IDO activity is a biomarker for DENV 
infection. 
The increase in IDO activity was statistically significant during the febrile, 
post-febrile and convalescence (7-10 days after defervescence) phases of the disease. 
The levels of IDO activity and the differences in IDO activity levels between DENV 
and OFI patients were greater during the febrile (p<0.001) and post-febrile (p<0.002) 
phases of the disease as compared to the convalescence phase (p<0.05). DENV 
viremia titers decrease rapidly at the end of the febrile phase of the disease (fever 
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day-1 to fever day +1), while the resolution of immune response occurs in the post-
febrile phase of the disease (124).  
These data suggest that the factors involved in activation of IDO gene 
expression are at their peak during the febrile and post-febrile phase of the disease but 
that the factors have not completely returned to normal levels by 7-10 days after 
defervescence. IFNγ is the most potent known inducer of IDO expression (12). Other 
cytokines such as IFNα/β, TNFα and IL-1β alone cannot induce IDO expression. 
However, TNFα and IL-1β synergistically enhance IDO expression induced by IFNγ 
(12). IFNγ, IFNα/β, TNF-α and IL-1β are detected at higher levels, than healthy 
donors, systemically in DENV patients. Levels of each cytokine return to normal 
values on different days in the post-febrile phase of the disease, which might 
contribute to the elevated IDO activity detected even on the convalescence day (8, 81, 
124).   
Another conclusion can be made from the levels of tryptophan and kynurenine 
detected in DENV patient serum. Significantly lower tryptophan levels were detected 
on all days in the dengue patient samples as compared to OFI patients. However, 
significantly higher kynurenine levels were detected only during the acute phase in 
dengue serum samples. IDO catalyzes the conversion of tryptophan to its stable 
metabolite kynurenine. The circulating levels of tryptophan might be lower in dengue 
patients due to higher IDO enzyme activity and lower oral intake of nutrients due to 
nausea, vomiting and weakness, clinical symptoms associated with DENV disease. 
However, since IDO catalyzes the conversion of tryptophan to its stable metabolite 
kynurenine, higher kynureneine metabolite levels will correlate with the level of IDO 
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activity. Hence, kynurenine levels might be a better indicator of IDO enzyme activity 
than IDO activity in DENV patient serum. If kynureneine levels are considered an 
indicator of IDO activity, there is a significant increase in IDO enzyme activity in 
DENV patients only during the acute phase of the disease. This hypothesis would 
suggest that the factor/s that induces IDO expression is suppressed after the febrile 
phase of the disease.  
Interestingly, the days of increase in serum kynurenine levels correlate with an 
increase in IFNγ levels and decrease in DENV viremia in DENV infected patients 
with DF (124), suggesting that IFNγ and not DENV might activate IDO gene 
expression in DENV-infected patients. IFNγ has been shown to be critical in the 
control of DENV replication in mouse and in vitro studies (125, 194, 230). Based on 
the importance of IDO activity in the antiviral activity of IFNγ against DENV in vitro 
and the correlation between the increase of IFNγ and significantly higher kynurenine 
levels, I speculate that IDO activity might play an important role in the antiviral 
activity of IFNγ against DENV in vivo. 
 
(iii) Antiviral function 
IFNγ-inducible IDO activity has been shown to play a role in regulating 
viruses (160). Heseler et al. (77) showed that 1-methyl-tryptophan (an analog of L-
Tryptophan that is a competitive inhibitor of IDO activity (31) inhibited the anti-
parasitic effect of IFNγ and IL-1 in an in vitro model of Toxoplasma gondii infection. 
IDO enzyme was also shown to play an important role in the antiviral activity of IFNγ 
against measles virus and in epithelial, endothelial and astroglial cells and herpes 
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simplex virus replication in HeLa cells (4, 160). Recent studies have found that the 
inhibition of T cell activation by IDO might be due to tryptophan starvation and/or 
production of T cell inhibitory metabolite of the kynurenine pathway (18, 105). We 
found significant lower levels of L-Tryptophan during the febrile and post-febrile 
stages of dengue illness and higher levels of L-Kyn during the febrile stage. The 
prevailing hypothesis is that the depletion of L-Tryptophan provokes a “starvation 
state” that results in inhibition of the growth of micro-organisms in vitro (32).  
Wu et al. have reported that IFNγ can inhibit DENV infection of DCs (78, 
125). Hence, we used DENV-infected DC to study the role of IDO in the antiviral 
mechanism mediated by IFNγ. Our results confirmed the observation that IFNγ 
inhibits DENV infection of DCs. Moreover, the IFNγ-mediated antiviral activity 
against DENV was significantly reduced in 1-MT-treated DCs. These results suggest 
that IDO activity plays an important role in the antiviral function of IFNγ against 
DENV, at least in DCs. 
IDO and one of its kynurenine pathway metabolites produced by monocytes 
and DCs have been shown to inhibit T cell proliferation and activation (18, 143, 150). 
We did not study the effect of increased IDO activity in DENV-infected DCs on T 
cell proliferation and activation.  However, DENV-infected DCs have been reported 
to be poor stimulators of allogeneic T cells (79, 135). One study observed that the 
proliferative responses of PBMCs to stimulation with DENV antigens, PHA, anti-
CD3 or tetanus toxoid were significantly decreased during acute DENV illness (135). 
The decrease in the T cell proliferation could be reversed by addition of accessory 
cells from a normal donor, suggesting that the deficit lay with the antigen-presenting 
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cells from the dengue patients. The possible role of IDO in the suppression of T cell 
proliferation in these models deserves further investigation. 
 
Satellite Muscle Cells Are Targets for DENV Infection 
Dengue virus (DENV) is a mosquito-borne flavivirus that causes an acute 
febrile disease in humans characterized by musculoskeletal pain, heachache, rash and 
leucopenia. Few autopsy studies have been performed to date with the goal to identify 
cellular targets of DENV infection and none of these studies have looked at muscle 
cells for the presence of DENV antigen or RNA. The cause for muscle affection in 
dengue patients is not understood. A recent study on Chikungunya virus, a virus 
which also causes persistent skeletomuscular pain and myalgia, was found to infect 
muscle satellite cells in acutely infected individuals (165). In my thesis, we performed 
flow cytometry and immunofluorescence microscopy to demonstrate that primary 
human muscle satellite cells are highly susceptible to infection by multiple DENV 
serotypes. We further demonstrated that DENV replicates in muscle cells, based on 
plaque assays showing high levels of DENV progeny in culture supernatants. These 
data demonstrate that DENV infects and replicates in human muscle satellite cells, 
which might play a role in myalgia observed during DENV infection in patients. 
However, first a clinical study should determine whether skeletal / cardiac muscle 
cells are targets for DENV in vivo. 
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Conclusion 
 
 Global gene expression analysis was applied in this thesis to identify genes 
important in the response of primary human cells to DENV infection. We 
hypothesized that dentification of endogenous antiviral proteins that regulate DENV 
infection would help in understanding and treating the disease. Type-I and type-II 
IFNs are considered critical in the regulation of DENV based on in vitro and mouse 
studies (51, 52, 78, 152, 153, 193). This thesis identified TRAIL, a type-I IFN-
inducible gene, and IDO, a type-II IFN-inducible gene, as playing important roles in 
Type-I and type-II IFN-mediated antiviral function against DENV, respectively.  
 The main challenge in treating dengue patients that present with severe 
clinical manifestations is that the symptoms of plasma leakage develop abruptly 
during the immediate post-febrile phase of the disease. Secondary DENV infections 
are associated with a markedly increased risk for DHF/DSS. However, there are no 
known biomarkers that can distinguish (i) secondary from primary infection or (ii) 
patients who are going to develop the severe form of the disease. This thesis 
identified sST2 and IDO as two biomarkers for DENV infection. In addition, sST2 is 
the first biomarker that can distinguish secondary from primary DENV infection. 
 Muscle affection is a frequent clinical symptom observed in dengue patients. 
In this thesis we found that DENV virus can infect and replicate in muscle satellite 
cells. Results from this section of the thesis strongly suggest that future clinical 
studies should be performed to determine whether muscle cells are targets for DENV, 
in vivo.  
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The ultimate goal of these studies was to identify (1) Potential targets to treat 
DENV infection and its immunopathology (2) Potential dengue infection biomarkers. 
Based on our results using global gene expression analysis, we believe that using the 
common response gene profile in the pathogen-susceptible cells and DENV-specific 
response gene profile in the cell appropriate for that particular disease model is a 
successful strategy that can be applied to identify important cellular response genes to 
other pathogens.  
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